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Long-term, persistent infection with high-risk strains of human papillomavirus (HPV) 
is the precursor of most cervical cancers and an increasing number of the head and neck 
cancers. While HPV vaccines can protect patients under twenty-five years old from 
possible infections, no HPV antiviral drugs are available for the definitive treatment of 
preexisting or future viral infections. To treat current or future HPV infections, drugs that 
selectively block virus-specific processes, but do not damage the host cells, are needed. 
The compounds developed in our group are unique Imidazole-pyrrole polyamides, 
analogs of natural products Distamycin A and Netropsin that function by interfering with 
natural virus-host interactions. 
Within the overall program of my group, my work focuses on three specific projects.  
The first project (Chapter 2) includes bioavailability LC-MS/MS analysis study of one of 
the leading compounds in plasma and whole blood. 
The second project includes the biophysical study of interactions between two 
polyamides, called TMG Asymmetric Hairpin Polyamides (TMG-AHP), and an essential 
viral DNA segment. The aim of this study was to determine where and how strongly the 
compounds bind to the viral DNA. In this work, two methods were used: the quantitative 
deoxyribonuclease (DNase I) footprinting method and the affinity cleavage assay (AC). 
The results are presented in Chapters 3 and 4. The remarkable findings resulted in binding 
location maps that help us to better understand the mechanism of action of AHPs and to 
address the question: what is the primary reason for neutralizing a virus by our 
polyamides. 
Based on the knowledge gathered from the results of the second project, a complex 
study (RNA-Seq) concerned with genome expression was performed. The aim of the third 
project is to find the common features and differences in the polyamides’ mechanism of 
action by quantifying messenger RNA (mRNA), after treatment of HPV infected skin cells 
with 8 different polyamides. 
In parallel with the analysis of human and viral transcriptome, a separate study 
concerned with the differential expression profile of seven DDR genes that are 
components of the homologous recombination (HR) pathway have been studied by RT-
qPCR method. The results are presented in Chapter 5 and 6. Data gathered from the third 
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Human papillomavirus. Polyamides as potential HPV antiviral drugs 
1.1 Abstract 
Long-term, persistent infection with high-risk strains of human papillomavirus 
(HPV) is the precursor of most of the cervical carcinomas (1, 2) and an increasing number 
of oropharyngeal squamous cell carcinomas, which represent 90-95% of head and neck 
cancers (3). While vaccines can protect the approved population from possible infections 
(4), no HPV antiviral drugs are available for the definitive treatment of preexisting or future 
viral infections. The approved population has a complex definition given the existence of 
a bivalent vaccine (for HPV16 and 18), a quadrivalent vaccine (for HPV6, 11, 16, and 18) 
and a recent nonavalent vaccine), but is generally stated as “boys and girls from ages 11-
13” to “men and women through age 26” (http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-
hcp.htm). To treat current or future HPV infections, drugs that selectively block virus-
specific processes, but do not damage the host, are needed. 
The compounds developed by our group are unique imidazole-pyrrole polyamides 
(PA), analogs of the natural products Distamycin A and Netropsin that function by inducing 
parts of the DNA Damage Response (DDR) (5, 6) and perhaps by interfering with natural 
virus-host interactions. Note that when this thesis project was started, no information about 
the DDR had yet been understood in a mechanistic sense and all focus was still on more-
traditional, sequence-specific DNA recognition rules for biologically-active polyamides. 
Within the overall program of my group, my work focuses on three specific projects.  
The first project (Chapter 2) includes a bioavailability LC-MS analysis study of one of the 
leading compounds PA25 (NV1042) in plasma and whole blood. 
The second project includes the biophysical study of interactions between two 
polyamides, called TMG Asymmetric Hairpin Polyamides (TMG-AHP), and an essential 
viral DNA segment. The aim of this study was to determine where and how strongly the 
compounds bind to the viral DNA. In this work, two methods were used: the quantitative 
deoxyribonuclease I (DNase I) footprinting method and the affinity cleavage assay (AC). 
The results are presented in Chapters 3 and 4. The remarkable findings resulted in 
binding-location maps that help to better understand the mechanism of action of AHPs 
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and to address the question: “What is the primary reason for neutralizing a virus by our 
polyamides?” 
Based on the knowledge gathered from published reports on gene expression with 
subsets of genes (7-9), the results of parallel studies with more-traditional but long, 
antiviral polyamides from our group (5, 6), and the second project (Chapters 3 and 4), the 
third project was devised, and a complex study (RNA-Seq) concerned with genome-wide 
gene expression, at the mRNA level, was performed. The aim of the third project was to 
find the common features and differences in the polyamides’ mechanism of action by 
quantifying messenger RNA (mRNA), i.e. determining gene expression, after treatment of 
HPV-infected skin cells with 8 different polyamides. In parallel with analysis of the human 
and viral transcriptome, a separate study concerned with the differential expression profile 
of seven DDR genes that are components of the homologous recombination (HR) pathway 
were studied by quantitative PCR, or the qPCR method. The results are presented in 
Chapters 5 and 6. Data gathered from the third project helped us further understand the 
mechanism of polyamide action so we may further develop future antiviral compounds to 
prevent cervical cancer and other HPV-derived diseases. 
Our group’s collaboration with NanoVir led to the discovery of compounds useful for 
eliminating HPV, unique large polyamides which decrease the amount of HPV DNA in 
infected cells and tissue and have great potential as possible drugs for the treatment of 
HPV infections (5, 6, 10-12). Biophysical results helped lead to further antiviral discoveries 
with new viruses, the polyomaviruses (U.S. Patent Appln. 14/818881, JK Bashkin, TG 
Edwards, C Fisher, GD Harris Jr, KJ Koeller, Antiviral compounds and methods for treating 
infections caused by double-stranded DNA viruses, 2015/11/19). 
 
1.2 Human papillomavirus (HPV) 
Human papillomaviruses (HPVs) are small dsDNA viruses which belong to the 
large family Papillomaviridae, a group of viruses that infect the stratified epithelia, 
keratinocytes, of the skin and mucous membranes. More than 140 types of human 
papillomaviruses have been fully sequenced and they are grouped by sequence homology 
into five genera. The high-risk HPV16, HPV18, and HPV31 are part of the alpha genus 
(13). Human papillomavirus possess a circular genome (HPV16 being 7904 base pairs 
long) that typically contains 8 genes. Genes and proteins of HPV are named according to 
timelines for viral gene expression as either early (E1, E2, E5, E6, E7) or late (L1, L2, and 
E4) (13-15). E1, E2, E4, E5, E6, and E7 are nonstructural proteins, while L1 and L2 are 
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structural proteins. The nucleotide sequence of L1, one of the late genes encoded by virus 
DNA, constitutes a basis for HPV classification. The different HPV types are divided into 
those preferentially infecting the skin versus those infecting mucosal surfaces (16).  
Among the mucosal HPVs, at least 15 types are considered high-risk (16), with 
HPV 16 and 18 accountable for >70% of HPV-induced cancers in the US (17). Cervical 
cancer is the second largest cause of cancer deaths in women worldwide (2). 
Approximately 11,000 women are diagnosed with cervical cancer in the USA annually and 
a third die of this disease (17). The high-risk HPVs are associated with cervical cancer 
and also with many penile, vulvar and anal carcinomas, and contribute to over 40% of oral 
cancers (1, 18). 
For the discovery that high-risk HPVs cause cervical cancer, Harald zur Hausen was 
awarded Nobel Prize in 2008, cementing the importance of knowledge related to HPV 
(https://www.nobelprize.org/nobel_prizes/medicine/laureates/2008/hausen_lecture.pdf). 
Both prior and subsequent to this, many studies have been published concerned with the 
HPV-induced carcinogenesis, which is still not completely understood (1, 16, 19). 
However, it is well-established that malignant transformation (16) is related to the 
persistent overexpression of HPV E6 and E7, the oncogenic proteins (15, 16, 20).  
Only a few HPVs are oncogenic, however, from which we infer that the protein 
activities of high-risk HPVs are different in a few aspects from the corresponding protein 
activities of HPVs associated with benign diseases, with limited oncogenic potential (20). 
Although the relative oncogenicity of E6 vary depending upon the HPV type, there is 
important overlap in the pathways altered by low- and high-risk HPV E7 (20). Carcinomas 
occur in the transformation zone of the cervix where the columnar and squamous epithelia 
meet (20). The intracellular milieu of the basal cells in this region may limit the completion 
of the productive life cycle (20, 21): therefore, if the productive life cycle cannot be 
completed (20), then no virions can be formed and the transformation of the cells might 
be favored. 
The integration of the viral genome into the genome of the host cell is common; 
it is not a necessary pre-requisite for the development of cancerous tumors. HPV 16, 18 
and 45 are more frequently found in an integrated state than HPV 31 and 33 (22). When 
integration of the viral DNA into the host’s chromosomal DNA occurs, no virions are 
produced. HPV integration usually occurs near or within known fragile sites (5) and often 
disrupts E2 expression (15). E2 autoregulates its own expression and regulates 
expression of E6 and E7. Disruption of E2 results in increased levels of expression of E6 
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and E7 which then induce the formation of tumors. A second path for malignant 
transformation could occur in cells that maintain viral episomes (1), and the expression of 
E5 would increase the activity of E6 and E7, leading to subsequent tumor progression (1).  
The E6 and E7 proteins provide functions necessary for the differentiation-
dependent life cycle of HPVs in addition to their roles in immortalization. These two HPV 
proteins also play critical roles in modulating immune evasion. Expression of E6 and E7 
oncogenes is regulated on the transcriptional level (23) in the viral long control region 
(LCR) (23), which is well-conserved in different HPV16 isolates (24).  
E7 proteins do not possess intrinsic enzymatic or DNA-binding activities but 
function by binding to several cellular factors (1) such as the Retinoblastoma tumor 
suppressor (pRb). pRb which normally prevents cell growth by inhibiting cell cycle 
progression is destabilized by E7. E7 protein propagate immortalization through 
interaction with proteins that control cell cycle progression (1). E7 proteins also target 
members of the interferon pathway (1). Interferons trigger the protective defenses of the 
immune system in response to the presence of viruses. The efficient binding of E7 to Rb 
family members and other cell cycle regulator proteins also results in the increase in the 
levels of the tumor suppressor p53, which limits cellular growth and increases the 
susceptibility of E7-expressing cells to apoptosis (1, 25).  
To diminish increased levels of p53, high-risk E6 proteins use several 
mechanisms to interfere with p53 functions (1), such as the formation of an E6–E6-
associated protein (E6AP)–p53 (1); formation of the trimeric complex results in p53 
degradation (1). Also, the interaction of E6 with the histone acetyltransferases prevents 
p53 acetylation, inhibiting the transcription of p53-responsive genes (1). High-risk E6 
proteins also activate transcription of telomerase reverse transcriptase (TERT), another 
essential step in immortalization (24, 25). E6 also interacts directly with components of the 
IFN response (1, 26). 
The expression of E6 and E7 is necessary but not sufficient for malignant 
progression (1). In the amplification phase of the HPV life cycle (see HPV lifecycle below), 
E6 and E7 promote the proliferation of undifferentiated and differentiated cells, in the same 
time allowing the avoidance of apoptosis (1). This phenomenon leads to an accumulation 
of DNA damage and genomic mutations (1).  
E5 protein can augment the function of E6 and E7 and contribute to tumor 
progression (1). E5 proteins are small, hydrophobic polypeptides approximately 83 amino 




1.2.1 The HPV lifecycle  
Three major phases in the HPV lifecycle can be detected (1) the initial 
amplification post infection (2) the non-productive or maintenance phase and (3) the 
productive phase, or amplification phase (Figure 1.1).  
All HPVs infect the basal cells of stratified squamous epithelia via micro abrasions 
(20) . Basal cells are undifferentiated skin cells and are the only proliferating (dividing) 
cells in normal epithelia (1). HPV virions infect the basal layer via heparan sulfate 
proteoglycans and integrin proteins (27). Integrin proteins are upregulated during wound 
healing and have been reported to play a role in viral attachment and entry. After being 
taken up, the viral particles travel to the nuclear membrane by the endosomal pathway 
(28), where the major and minor capsid proteins (L1 and L2) are left behind and the viral 
genome in the form of a chromatinized double-stranded DNA circular episome is 
transported into the host cell nucleus (27). After membrane penetration of mitotic cells and 
nuclear import, the virus locates to nuclear bodies, or nuclear domains, known as ND10 
(28). It was proposed that ND10 bodies are associated with regions of DNA damage in 
uninfected cells (8). In the basal cells, the viral genome is maintained extrachromosomally 
(20) as episomes that can be replicated independently from the host chromosomal DNA.  
In the initial amplification stage, the viral genome replicates but maintains a low 
copy number as a consequence of the expression of the E8^E2 transcript which is the 
repressor of viral transcription and replication (29-31). To produce a persistent infection, 
the virus has to be able to evade immune responses. HPV is effective at evading 
immunological detection and produces only a slow and weak immune response which 
varies among patients (32). Not just in the initial amplification stage but during the whole 
lifecycle of HPV, the exposure to the host immune system is limited. Infections do not 
produce viremia, the presence of viruses in the blood, and a limited load of antigenic HPV 




Figure 1.1. Episome copy numbers in different phases of replication. Adapted from (8) 
The maintenance phase is the phase in which the episomal DNA is maintained at 
a few hundred copies of episomes per cell and no viral structural proteins are produced 
(15, 20). The W12E cervical keratinocyte cells were purified from a clinical isolate and are 
undifferentiated cells which harbor 100-500 viral episomes per cell (5, 6, 10). These cells, 
which mimic cells harboring viral episomes in the maintenance phase, were used as the 
model for the gene expression studies. They were a kind gift of Dr. Paul Lambert of the 
Medical School at The University of Wisconsin, Madison.  
To transition or progress to the maintenance phase, the viral genome has to be 
tethered to beneficial regions of chromatin and to modulate DDR responses. In the 
maintenance phase, depending on the HPV type, replication of the episomes occurs 
during S-phase along with the host genome, or by a random choice mechanism (33). High 
levels of E1 promote mostly random choice replication in W12 cells (33) and trigger a DDR 
response imposed by ATM (34) to ensure replication of the virus. In the S-phase, the 
episome is (or may be, see later discussion) attached to the host chromatin using E2 as 
an intermediate. E2 binds the episome on its DNA binding domain and also binds the 
BRD4.  
The BRD4 tethers the episomes to the host chromatin (at fragile sites as 
demonstrated in C-33 cells (35)) to ensure replication. BRD4 is important for genome 
tethering during maintenance and as well as a viral replication center initiator present in 
the amplification phase (8, 36). This tethering mechanism ensures that the low copy of the 
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viral genome is retained in the nucleus and is distributed to daughter cells (36). The 
binding model for HPV18 is shown in Figure 1.2. 
 
Figure 1.2. Model of E2-mediated Tethering of the Viral Genome to Host Chromatin (36) The DNA-
binding domain is of the HPV18 DNA binding domain bound to DNA (shown in light purple) from 
the PBD file 1JJ4 (36).  
 
Binding of E2 to Brd4 is not sufficient for tethering the viral episome to the mitotic 
chromosome; E2 also has to bind ChIRI (37, 38). Recently the HPV16-BRD4 complex 
was analyzed by bimolecular fluorescence complementation experiments (8, 39) and with 
the help of experiments where E2 is expressed as a GFP-fusion protein (40). Many studies 
concerned with the role of BRD4 as a key regulator of transcription also found that BDR4 
may be associated with DDR elements and also associates with fragile sites (35). BDR4 
is an insulator chromatin that can modulate the signal of DNA damage (41). 
However, new studies display a model in which the viral episomes (HPV 31) bind 
to the host chromatin in a way that is independent of BRD4 protein (42). This controversy 
has not been resolved and is complicated by the fact that the majority of studies on BRD4 
were done with chimeric human/bovine papillomavirus systems and/or with E2 highly 
overexpressed. 
Viral replication centers are distinct nuclear foci that contain recruited nuclear 
replication factors associated with the host DDR; with the help of which viral genomes are 
replicated. Replication foci can be detected in differentiated cells (8). BRD4 is initially part 
of the replication process by concentrating viral proteins in specific regions of host 
chromatin (43). It was shown that DDR factors are present in the replication centers in the 
case of differentiated keratinocytes (19).  
In the amplification stage of the viral life cycle, a rapid increase of viral DNA and 
virion production also occurs (8, 20). The synthesis of virions, or viral particles, that are 
able to shed and infect other organisms occurs only after cells have differentiated, 
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migrating towards the outer layer of the epithelium (15, 20). For virion production, the late 
genes L1 and L2, which code for capsid proteins, must be expressed (16). The genome 
amplification in this stage is thought to be a rolling cycle type and may be linked to DDR 
(9). Recent findings identified SMC1 (cohesin protein) and CTCF (insulator transcription 
factor) as critical regulators of differentiated high-risk human papillomaviruses (42). 
Viral gene expression is controlled through two viral promoters. The early 
promoter (p97 for HPV 16, Fig.1.3) is located in the upstream regulatory region (URR) (8) 
adjacent to the E6 open reading frame (ORF) and is active in the infection process and 
during the maintenance phase (44). Promoter p97 directs expression of the E1 and E2 
replication proteins (8), which leads to the establishment of viral genomes, as well as the 
expression of the viral oncoproteins E6 and E7 which regulate cell cycle progression. 
Transcription stops at the early polyadenylation (poly(A)) site AE and the transcript is 
processed by using the early splicing signals (45). 
As HPV-infected cells differentiate, the late HPV promoter p670 (Figure 1.3) 
located in the middle of the E7 ORF is activated (44), leading to expression of late gene 
products such as E4, L1, and L2, and increased levels of E1 and E2 (15, 46). In 
differentiated cells, the transcripts expressed from the late promoter utilize a late poly(A) 
signal, AL, and late splicing signals (45). The early and late splicing signals compete for 
the splicing factors, so their usages are exclusive (45). 
 
Figure 1.3. The HPV circular dsDNA genome structure. Viral genes are transcribed in clockwise 
direction. The LCR contains a DNA replication origin and functions as a regulator for DNA 





1.2.2 The DDR’s role in viral episome maintenance (Chapter 5) 
In general, infection by DNA viruses induces the activation of many cellular pathways, 
including those involving p53, stress, apoptosis and the DNA damage response (DDR) 
(7). The DDR can detect foreign DNA and can also sense aberrant DNA structures that 
form as a result of chromatin changes during nucleic acid transactions such as 
transcription and replication (47). DDR response is also triggered by changes in chromatin 
structure (35).  
The presence of HPV’s circular dsDNA episomes initiates a DDR response. The HPV, 
a small virus, which contains no polymerase, just two replication proteins (E1 and E2) 
employs some of the DDR elements for its replication.  




Figure 1.4. DNA damage response to single-stranded and double-stranded breaks (48). ATM: 
Ataxia-telangiectasia mutated kinase; ATR: Ataxia-telangiectasia and RAD3-related kinase; 
ATRIP: Ataxia-telangiectasia and RAD3-related kinase-interacting protein; RPA: Replication 
protein A; TOPBP: Topoisomerase binding protein. 
 
RPA coats single-stranded DNA and is subsequently recognized by an ATR-
ATRIP complex (48). The RAD9-RAD1-HUS1 (9-1-1) complex binds to the 5′ overhang 
near the exposed ssDNA and brings in TOPBP1 which activates ATR in the presence of 
ATRIP (48). ATR phosphorylates many downstream targets including Chk1, the cell cycle 
checkpoint kinase, and p53 (48). When Chk1 is phosphorylated, it will arrest the cell cycle 
(34). 
Double-stranded DNA breaks are detected by the Mre11–Rad50–Nbs1 complex, 
which promotes monomerization and autophosphorylation (activation) of the ATM kinase 
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(48). Activated ATM will lead to phosphorylation and activation of its downstream effector, 
Chk2 kinase, and p53, H2AX (γH2AX) and Nbs1, among many more targets (48).  
The ATM pathway activated by ds-breaks and the ATR pathway activated by 
single-strand breaks were thought to function in parallel. However, recent studies 
reviewed by Hong and Laimins (15) indicate that these two pathways are linked to each 
other. ATR seems to be subordinated to elements of ATM. The ATR–CHK1 pathway 
requires activation by ATM. ATR is sensitive to radiation-induced ds-breaks and the 
MRE11/RAD50/NBS1 (MRN) complex that induces autophosphorylation of ATM is also 
needed for ATR activation (15). 
The present study will involve W12E cells, undifferentiated keratinocytes which 
maintain the episomal high-risk HPV16 genome. Four viral proteins, E1, E2, E6, and E7, 
are required for the maintenance of viral DNA in cell cultures (45). The capsid proteins L1 
and L2, essential for the infectious particle (virion) formation, are not expressed in 
sufficiently high levels in the undifferentiated cells that will be used. 
1.3 Polyamides as potential HPV antiviral drugs 
N-methylpyrrole-N-methylimidazole polyamides (PA) are versatile homologs of the 
naturally occurring antibiotics Distamycin A and Netropsin, small, crescent shaped 
polypyrrole peptides that bind to repeating A/T tracts (49) in minor grooves with modest 
affinity and specificity (49-51). Distamycin has antitumor and antiviral proprieties but also 
a high toxicity (10, 49, 52). 
To overcome the high toxicity but maintain antitumor and antiviral properties, 
polyamides were designed following the Distamycin model. By introduction of imidazole 
(Im) building blocks, recognition of G and tracks that include G became possible, leading 
to reported pairing rules (53, 54) pyrrole (Py) binds to the three nucleotides which present 
H-bound acceptors in the minor groove A, T, and C. γ-turn, γ-aminobutyric acid binds to 
A/T or T/A nucleotides. The cationic tail (Ta) aids binding and recognizes A/T or T/A 
nucleotides; β-alanine (β-spring) binds to A, T or C. Then β-alanine units confer additional 
flexibility and better follow the DNA curvature (54, 55). The flexibility of the β units can 
help optimize the interactions of polyamides with the targeted DNA bases, however, the 
number and position of the substitutions influence the binding affinity of polyamides in the 
minor groove of DNA, though this level of sophistication was ignored in the original 
literature but was recently reported (56-58). Polyamides specifically recognize and bind 
with high affinity to dsDNA in minor groove regions by hydrogen-bonds (49, 59).  
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The binding of PAs is followed by alterations of the dsDNA shape by widening the 
minor grove, narrowing the major groove (54, 60), and stiffening the double helix (61).  
By binding with high affinity in the minor groove, the small polyamide molecules 
can fulfill different functions such as the regulation of gene expression, or the molecules 
may be used as molecular probes. Polyamides are able to displace many proteins from 
DNA interfering with gene expression at transcription levels (62). Also, PAs can be 
specifically designed to bind to recognition sites of the transcription factors (49, 63) of 
dsDNA, silencing aberrant gene expression or infectious diseases in this way. A strategy 
of suppressing viral DNA transcription was successfully employed for destabilizing the 
Epstein-Barr virus (64).  
Conjugated polyamides can function as site-specific alkylating agents able to 
covalently modify DNA (49). Alkylated DNA can mimic methylated DNA, interrupting 
transcription and selectively silencing targeted genes (49). A possible chemotherapeutic 
choice for cancer treatment is the use of polyamide-alkylator conjugates to silence the 
oncogenes (49, 65). Bifunctional PAs could also be used to alkylate human telomeres 
(1000 or more tandem repeats of a short G-rich sequence, TTAGGG, on the 3’ end of 
each chromosome (66) ) and abrogate the increased telomerase activity of cancer cells 
(49, 67). Polyamide-peptide conjugates can function as synthetic transcriptional activators 
as well (49). Recent work showed the results of coupling a hairpin polyamide to a 
suberoylanilide hydroxamic acid (SAHA) moiety (68), known to act as a histone 
deacetylase inhibitor with broad epigenetic activity (49). Histone acetylation will loosen up 
the nucleosome, allowing the genes to be expressed (68, 69).  
Polyamides are also used as molecular probes. When PAs bind to dsDNA match 
sites, the fluorescent signal produced by the polyamide-fluorescent dye conjugates is 
enhanced, allowing them to be used in cellular localization studies (70). Although the 
fluorescent dye used in imaging experiments can affect the cellular uptake of PAs, many 
studies (59, 71, 72) provide significant results to provide evidence that PA uptake is 
achievable over a wide range of PA molecular weight (up to 4000 Da) and cell types (73).  
PAs accumulate within cells by either passive diffusion, regardless of their 
molecular size (73, 74), or active diffusion, which is energy-dependent, such as in the case 
of HeLa cells (74). Effective cellular uptake of PAs was also observed in a range of human 
primary keratinocytes, including keratinocytes harboring HPV infections (5, 10). Therefore, 
the process of PA uptake into cells is extremely well studied. Efficient PA uptake was also 
exhibited in some animal studies (71, 75). Molecular size does not influence the cellular 
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uptake (polyamides can cross plasma membranes) (73). However, the permeability of the 
nuclear membrane is sometimes reduced for larger polyamides (73). Many studies show 
that PA uptake in cells is achievable, but varies with cell line and PA structure (imidazole 
content, structure of the “tail”, hydrophobic qualities, β-alanine (57), and gamma turns (54, 
71, 74)). According to cell and animal studies, some polyamides have cytotoxic effects 
(76-78), while others, such as the case of anti-HPV polyamides that decrease viral DNA 
levels, exert their effects without toxicity. Sometimes, efficiency is diminished or impaired 
because polyamides are not able to reach the target destination, the nucleus of the cells. 
Quantitative measurements have shown that the concentration in the nucleus of 
polyamide–fluorescein conjugates is lower than the media concentration and differs 
according to the cell line (75). Accumulation of polyamides in the cytoplasm (79) and 
sequestration in acidic vesicles was evidenced by confocal laser scanning microscopy 
and flow cytometry measurements (73). Multidrug resistance (MDR) causes polyamides 
to be stored in acidic vesicle in some transformed cells; nevertheless, uptake can be 
improved using inhibitors of MDR (70) 
Earlier studies show that much of the DNA in the nucleosome (the elemental 
repeating unit of all eukaryotic chromatin (80), consisting of histone proteins around which 
146 bp of DNA are wrapped (80)) is freely accessible for polyamide binding in the minor 
groove (54, 81). The sites on nucleosomal DNA facing away from the histone octamer and 
the sites partially facing the histone octamer are fully accessible for DNA binding (80) 
(PDB: 1M18, 1M19, 1M1A). Polyamides not bind where sites are completely blocked by 
interactions with the histone octamer (81). The structure of the histone octamer and its 
interaction with the DNA is unaffected by PA binding (80). However, the nucleosomal DNA 
undergoes structural changes at PA binding sites and the adjacent regions, such as the 
widening of the minor groove and alterations of the DNA twist angles, which are 
propagated to distant regions (80). The details of the changes upon PA binding are 
revealed by the crystal structures of the nucleosome (80). The study also suggested that 
nucleosome-bound DNA is capable of adjusting its structure to allow binding.  
In vivo studies suggest that polyamides have an unexplained preference for some 
nucleosomal DNA binding positions. Research done in Dervan’s lab revealed that a 
polyamide-DNA alkylator, chlorambucil, with high affinity, binds solely to two of the perfect 
matching sites of the H4C (highly expressed histone protein in cancer cells) gene. No 
other gene downregulation (a consequence of the polyamide binding) was observed, even 
if possible binding sites of this polyamide are present many times in the human genome 
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(77). The binding of the polyamide to the H4C gene in colon cells may be caused by 
differences in nucleosome placing or nuclear localization of PA (59, 74, 77). Other studies 
focusing on nuclear chromatin access by a polyamide-chlorambucil conjugate showed that 
PA binding was restricted to a limited number of genes (82).  
In conclusion, even though nucleosomal DNA is partially accessible for high-affinity 
binding, in vivo studies show that the binding patterns of PA to a certain cell type genome 
are not completely predictable. Comprehensive binding studies are required to understand 
the complex, dynamic processes that take place in the cells. 
A special class of polyamides and potential drug candidates, long N-
methylpyrrole-N-methylimidazole hairpin polyamides, were synthesized in Dr. Bashkin’s 
lab using Boc-chemistry solid phase synthesis procedure (83-85). These polyamides were 
found to have anti-HPV activity against three different HPV genotypes: HPV16, 18, and 
31 (5, 10, 26). Binding in the minor groove of dsDNA (54, 57, 60) causes structural 
alterations of supercoiled dsDNA, perhaps causing ssDNA exposure or double strand 
breaks (DSBs) within HPV episomes, but in any case resulting in the activation of DNA 
damage response (DDR) pathways (6). Activation of DDR genes eliminates (causes 
enzymatic destruction of) viral episomes without having significant effects upon cell growth 
or apoptosis (6). These special polyamides have the ability to decrease HPV16 episome 
levels in undifferentiated W12E cell monolayers and tissue culture in the absence of 
integration of viral DNA.  
In the present study, a new class of derivatives of antiviral polyamide NV1042, also 
called PA25, was used.  These compounds have a modified N-terminal capping group, 
1,1,3,3 tetramethylguanidine (TMG) or guanidine at the N-terminus. Previous work results 
(NanoVir, LLC, Table 1.1 and 1.2) demonstrated the antiviral activity of the compounds 
by attesting the decrease of HPV DNA levels in human keratinocytes by more than 90% 
in cells that maintain HPV16, HPV18, or HPV31 DNA. Moreover, the 
tetramethylguanidines (TMG) displayed as much as a 5-fold greater efficiency in human 
keratinocyte cell culture against HPV16, 18 and 31 than the best dIm-terminated members 





Table 1.1. Polyamides used in the following studies. The IC50 and IC90 values measured for W12E 
cells were determined by T. G. Edwards in the Fisher lab, unpublished data. 
 







NV1011 (PA11) NOT ACTIVE NOT ACTIVE NOT ACTIVE NOT ACTIVE 
NV1028 (PA1) 0.100 1.113 0.717 >10 
NV1042 (PA25) 0.036 0.351 0.056 1.462 
NV1078 0.046 0.307 0.030 0.091 
NV1087 0.031 0.200 0.024 0.297 
NV1111 0.017 0.121 0.018 0.136 
NV1113 0.304 >10 0.228 >10 
NV1115 0.103 0.378 0.167 0.937 
 
Table 1.2. Sequences of polyamides (PAs). PA1 and PA25 are the original preclinical lead 
compounds. Abbreviations: Im represents N-methylimidazole, Py is N-methylpyrrole, β is β–
alanine, γ is γ-aminobutyric acid, and Ta is CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-
methyldipropylamine. The polyamides were synthesized by solid phase synthesis as previously 




Polyamide (PA) PA sequence N-terminal group 
NV1011 (PA11) ImPPIm-γ-PPPPβDp Im 
NV1028 (PA1) ImPPβPPP-γ-PPβPPPPβTa Im 
NV1042 (PA25) ImPPβPPImβPP-γ-PPβPPPβPPPβTa Im 
NV1078 TMG-PβPPImβPP-γ-PPβPPPβPPPβTa TMG 
NV1087 TMG-PPPβPPβPIm-γ-PβPPβPPPβPβTa TMG 
NV1111 Guan-PPPβPPβPIm-γ-PβPPβPPPβPβTa Guan 
NV1113 TMG-ImPPβPPP-γ-PPβPPPPβTa TMG 





Analytical Studies of Polyamide Content in Plasma and whole Blood 
2.1 Introduction 
This chapter includes the LC-MS analysis of different blood fractions provided by 
MPI RESEARCH (2026-006) and whole blood analysis of K2EDTA-treated rat blood 
(Fisher Scientific). Prior to this study, animal studies (MPI 2026-003) were conducted by 
WIL Research Laboratories, LLC, 1407 George Road, Ashland, OH  44805-8946, using 
an analytical method developed by MPI Research, a subsidiary of WIL Research, and 
qualified under MPI Research Study Number 2026-001.The project was approved by NIH 
and animal safety was approved by the Institutional Animal Care and Use Committee 
(IACUC) established by WIL labs. 
Polyamide (NV1042) was administrated to female Sprague Dawley (SD) rats to 
characterize its pharmacokinetic properties, acute and subacute toxicity, estimate the 
maximum tolerated dose (MTD), and evaluate the toxicokinetics of the polyamide in the 
female rats.  The MTD is a dose that does not produce mortality, more than a 10% 
decrement in body weight, or significant clinical signs of toxicity.  
Since the absorption following topical application (intra-vaginally), the intended 
route of clinical administration, was apparently insufficient and special formulations for oral 
bioavailability were not available, the intravenous route was selected for drug 
administration in order to determine the NV1042 concentration in blood compartments. 
This method was thought to be the only alternative to achieve toxicologically-relevant 
systemic plasma concentrations. (MPI 2026-002, 2026-003).  
NV1042 polyamide was administered by a slow (60 + 5 s) intravenous injection 
(IV) at 1, 2, or 5 mg/kg doses. A detailed protocol of the animal studies can be found in 
MPI 2026-002 research study, cited above. For plasma analysis, blood samples were 
collected in tubes containing K3EDTA as an anticoagulant. The blood samples were 
centrifuged and the plasma was stored at -50 to -900C until analyzed. 
Polyamide plasma concentration levels were quantified by the LC-MS/MS MPI method 
(details in MPI 2026-0010B-01,2 Analytical method). This method was adapted for our 
work as described in the paragraph 2.2.6 LC-MS Analytical Method.  
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Separate analyses for plasma spiked with polyamide as well as plasma of whole 
blood samples extracted from animals after treatment were performed. The results were 
different. The polyamide was quantified in plasma samples but not in plasma samples 
originating from animals after they received treatment. Plasma concentration levels after 
the intravenous administration of polyamide NV1042 were not detected by the MPI 
method. (The company claimed that all polyamides were metabolized in the animals.)  
Opposing the Contract Research Company’s inference, it was hypothesized that 
D5W (5% dextrose, the vehicle used in animal studies) intravenous (IV) solutions 
interfered with polyamide analysis and might have caused the polyamide to precipitate 
during plasma processing. The differences in the bioavailability of the two situations arises 
from the differences between the polyamide sample preparations. In the case when 
plasma was spiked with PA, the PA was dissolved in DMSO first and the plasma 
concentrations were quantifiable. On the other hand, when PA dissolved in D5W was 
injected into the blood stream and analyzed from the subsequently extracted blood 
plasma, concentration levels were too low. D5W might have helped absorption, for 
example into the cells, though the team leaders did not consider this at the time; they were 
more concerned with inappropriate precipitation by the plasma purification procedure.  
The purpose of this work was both exploratory and rather desperate: animals had 
been sacrificed in the course of carefully designed experiments. Without proof that the 
compound was present, the FDA would not accept data from the study to establish a 
maximum tolerated dose. This would mean the inacceptable waste of living animals and 
the loss of large sums of research dollars and large amounts of test compound prepared 
at great expense and effort. If the compound could be found in the samples, as Dr. Bashkin 
believed it must be, then large portions of the study would be salvaged in spite of the loss 
of pharmacokinetic data. 
2.2 Materials and Methods 
2.2.1 Polyamide PA25 (NV1042) and Internal Standard NV1057 
The polyamide used in the present investigation is one of the leading HPV antiviral 
compounds PA25 (NV1042) (5, 10, 12, 86). NV1042 is a large hairpin polyamide with the 
following structure: ImPP-β-PPIm-β-PP-γ-PP-β-PPP-β-PPP-β-Ta, where: Im represents 
N-methylimidazole, Py is N-methylpyrrole, β is β–alanine, γ is γ-aminobutyric acid, and Ta 
is CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-methyldipropylamine (Figure 1). NV1042 




Figure 2.1. Structure of NV1042. The compound, ImPPβPPImβPPγPPβPPPβTa and the 
4 counterions (TFA), has the molecular weight 2982.79 
 
Polyamide NV1042, a member of the programmable heterocyclic oligomers N-
methylpyrrole–imidazole polyamide class of the hairpin type, has a unique importance, 
having anti-HPV activity against three different HPV genotypes HPV16, 18, and 31 
(Chapter 1, Table 2) (10, 87, 88). The binding of NV1042 by noncovalent bonds in the 
minor groove of dsDNA was extensively studied (5, 10, 86). As a consequence of the 
binding, structural alterations of superhelical dsDNA cause ssDNA exposure or double 
strand breaks (DSBs) within HPV episomes resulting in the activation of DNA damage 
response (DDR) pathways (6). Activation of DDR genes eliminate and degrade the viral 
episomes without significantly affecting cell growth or apoptosis (6). This special 
characteristic made NV1042 an excellent drug candidate to be a subject in the animal 
studies.  
As internal standard polyamide NV1057(KJK5115) was used.  
 
 
Figure 2.2. Chemical structure of NV1057 internal standard 
Table 2.1. Positive electrospray ionization of the NV1057, the most abundant protonated 
ions, generated at 28 eV collision energy are highlighted (data collected on LC-MS/MS 
Quadrupole TOF Bruker Maxis, Dr. Bythell’s instrument). 
 
Polyamide Exact mass [M+H] [M+2H]/2 [M+3H]/3 [2M+H] [2M+3H]/3 [3M+4H]/4 




2.2.2 Plasma and Blood Pellet Provided by MPI Research 
Four refrigerated pellets and a total of 8 frozen plasma samples (Analytical method, MPI 
RESEARCH, LC-MS/MS analysis for NV1042 in SD Rat K3-EDTA 2026-006) were 
received on May 2012 from Christine Wisniewski, MPI Research, Mattawan, MI. The 
received samples were processed according to the “Analytical method, MPI RESEARCH, 
LC-MS/MS analysis for NV1042 in SD Rat K3 -EDTA 2026-006” protocol. These samples 
were collected on 4/27/2012. The summary of the protocol for processing the samples is 
provided in the following four paragraphs. 
Blood samples (at least 4 mL each) were collected from 3 rats into tubes containing 
K3-EDTA anticoagulant. Whole blood samples were transferred (and pooled) into a large 
conical tube, inverted gently and equally divided into 2 approximately equal aliquots.  
From one aliquot (whole blood), four aliquots (1 mL each) were placed into plastic 
tubes and identified as A, B, C, and D. The whole blood samples were spiked with the 
polyamide solution to achieve the required concentrations and then spun down to harvest 
plasma and the pellets. The collected samples were: 
4 plasma samples aliquot A (0 mg/mL PA, received no polyamide treatment), aliquot B 
(1000 ng/mL PA), aliquot C (5000 ng/mL PA), and aliquot D (25000 ng/mL PA) and 
4 pellet samples:  aliquot A (0 mg/mL), aliquot B (1000 ng/mL), aliquot C (5000 ng/mL), 
and aliquot D (25000 ng/mL). 
The second aliquot was centrifuged at 3000 RPM for 10 minutes at room 
temperature.  The resulting plasma was extracted and separated in four aliquots (1 mL 
each) into plastic tubes.  Plasma blood (not whole blood) was spiked to prepare 4 other 
plasma aliquots. The aliquots were identified as plasma aliquots AA (0 mg/mL), BB (1000 
ng/mL), CC (5000 ng/mL), and DD (25000 ng/mL).   
All PA stock solutions were prepared in D5W (5% Dextrose, USP) and added 
directly to either the blood or plasma samples. The dose formulations were vortexed for 
1-2 minutes, then sonicated until complete dissolution. 
2.2.3.  Whole Blood  
  Rat whole blood in K2EDTA (50-412-666) was purchased from Fisher Scientific. 
The blood was aseptically drawn from normal healthy animals; but it was not intended for 
use in transfusions or other medical applications. The rat blood was stored in the 
recommended conditions, 2-8 °C, and remained stable for the purposes of these 




2.2 4. Plasma Sample Preparation  
Plasma samples were prepared for LC-MS analysis by mixing 100 µL of plasma 
with 25 µL of working internal standard (WIS) solution. The WIS was 10 µg/mL NV1057 
and was prepared by diluting a 100 µg/mL NV1057/DMSO solution with WIS diluent 
solution. WIS diluent being: DMF/HPLC grade Water/FA (50:50;0.1, v/v/v). Formic acid 
was used to prevent the compound from aggregating in the solvent and from sticking to 
the container.   
After the internal standard was added and gently mixed, 75 µL of precipitation 
solution was also added. The protein precipitation solution was either acetonitrile with 
0.05% acetic acid or methanol (89). The mixture was vortexed, and 200 µL precipitation 
solution was added again. The mixture was vortexed again for 10 minutes and centrifuged 
at 4000 rpm. The polyamide was extracted with DMSO from both pellet and supernatant 
obtained after centrifugation.  
2.2.5 Pellet Sample Preparation. Extraction of Genomic DNA from Spiked 
Whole Blood and Pellet. 
The extraction of genomic DNA from blood cells was performed using the DNAzol 
BD (Life Technologies) procedure at room temperature (90).  The lysis of the cells was 
performed with DNAzol lysing solution, a guanidine-detergent that hydrolyzes RNA and 
allows a precipitation of DNA from a cell lysate. (1 mL DNAzol + 0.1 mL liquid sample). 
The DNA precipitation with 100% ethanol or isopropanol (lysate + 0.5 mL ethanol/1 mL of 
DNAzol) was followed by the precipitated DNA wash (1 mL of 75% ethanol, 2 times). 
Subsequently, DNA was solubilized with 8 mM NaOH. DNA isolated with a DNAzol regent 
does not resuspend well in water or Tris buffer.  
To separate the polyamides from DNA, DNA digestion was performed with a DNA-
FreeTM–Applied Biosystems (AM1906) kit which contains deoxyribonuclease I (DNase I). 
DNase I digest single- and double-stranded DNA to oligodeoxyribonucleotides containing 
a 5’-phosphate. DNase I is suitable for removing DNA from samples containing proteins.  
Following the digestion of DNA, protein precipitation was performed by two 
methods. The first method used was precipitation with acetonitrile + 0.5% acetic acid, the 
method proposed by MPI. The second method was based on work done by the Dervan 
group and employed methanol (91). The polyamide was extracted from every fraction, 
supernatant or pellet, obtained after centrifugations. For polyamide extraction DMSO was 
used. If the samples contained cell residues that cannot be removed by centrifugation, the 
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samples were filtered and the filter was washed with DMSO until all polyamide was 
recovered.  
2.2.6 LC-MS Analytical Method  
The sample concentrations of polyamide NV1042 were analyzed by LC-MS using 
an Agilent 1100 system (Agilent, Santa Clara, CA, USA) connected with an Agilent 1956B 
MSD, or single quadrupole mass spectrometer. HPLC separation was accomplished using 
a Phenomenex Jupiter Proteo (C12), 4.6 x 50 mm, 4 µm particle size, 90 Å pore size, part 
number OOB-4396-EO column. The column temperature during the experimental analysis 
was maintained at 40 °C. The mobile phase A consisted of 100% HPLC grade water with 
0.1% TFA. The mobile phase B consisted of 100% HPLC grade acetonitrile. The following 
gradient program was used: 5% B (0-3 min, 2.0 mL/min), 60% B (4 min, 2.0 mL/min), 60% 
B (4.25 min, 2.0 mL/min), 5% B (5.5 min, 2.0 mL/min), and 5% B (6.5 min, 2.0 mL/min). 
The total run time for a sample was 6.5 min. The auto-injector temperature was maintained 
at RT. The needle wash solution was MeOH. The injection volume used varied between 
1 and 100 µL according to the sample concentration. The detection wavelength was set 
to 300 nm (Figure 2.3 and 2.5). Data were processed with Agilent ChemStation software, 
which was also used to control the HPLC/MS. Positive-mode electrospray ionization of the 
compound NV1042 produced abundant, protonated, molecular ions (M+3H+) 3+/3 =842; 
(M+2H+) 2+/2 = 1264; (M+H+) +/1 =2526.8 (2M+3H+) 3+/3 = 1684.5 (Figure 2.3). These ions 
were generated by the parent species at HPLC retention time 2.9 min. Note that in order 
to see good UV/Vis spectra by diode array detection, high concentrations of compound 
were injected relative to what was necessary for mass spec detection alone. These high 
concentrations were the likely cause of the gas-phase aggregates such as [2M+3H]3+ that 





Figure 2.3. Representative mass spectra of NV1042 precursor ions. The positive 
electrospray ionization of the NV1042 compound produced abundant protonated 
molecular ions (M+3H+) 3+/3 =842; (M+2H+) 2+/2 = 1264. 600<m/z<2300 vs ion current 
 
2.3 Results and Discussion 
Whole blood fractionation was performed for separation of the blood plasma from 
the blood pellet. Blood plasma, which represents 55% of total blood volume, is the 
noncellular liquid part that contains dissolved proteins, glucose, clotting factors, 
electrolytes, hormones and carbon dioxide (92). 
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The blood pellet is composed of two fractions. The buffy coat consists of 
leukocytes (white blood cells) mixed with platelets, and erythrocytes or the red blood cells. 
It was proposed that the disappearance of the polyamide molecules in the MPI 
samples was caused by the molecules being “trapped” in the cells. To recover the 
polyamide, the pellet originating from the sample treated with the highest polyamide 
concentration was studied first. Every fraction obtained after centrifugation steps was run 
on HPLC.  
A standard curve used for quantification was prepared by mixing 1 mL DNAzol + 
0.2 mL NaOH (8mM) + 6.4 µL 0.1 M HEPES with various concentrations of polyamide 
(Table 2.1, Figure 2.4). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) is a 
zwitterionic organic buffering agent and was used to adjust the pH to 8.4. 
 
Table 2.1. HPLC peak areas obtained following the pellet sample preparation procedure. 
(0.1 mL PA + 1 mL DNAzol + 0.2 mL NaOH (8mM) +6.4 µL HEPES 1M) 
 
Sample Concentration (ng/mL) Peak area (mAU*s) Injection volume(μL) 
D1 25000 1020,74988 50 
D2 5000 198,15282 50 
D3 1000 30,21107 50 




Figure 2.4. The standard curve, as determined by linear regression, displayed good 
linearity (R2 > 0.99) over the range tested from 50 ng/mL to 25000 ng/mL NV1042. 






















The quantity of PA recovered from MPI pellet samples (D and DD spiked with 2.5 
µg/mL polyamide) was low but detectable. The highest recovery was 33%. However, when 
fresh whole blood was spiked with 2.5 µg/mL NV1042 a higher quantity was recovered 
from the blood pellet (cells). When plasma was spiked with the polyamide, the recovery 
was almost complete. More than 50% of the polyamide precipitated with the protein 
fraction, and the rest was found in the supernatant of the spiked plasma. The highest 
protein recovery results were obtained when acetonitrile + 0.5% acetic acid was used for 
protein precipitation. It was hypothesized that D5W aided absorption of polyamide into the 
cells. (Note: this hypothesis about D5W aiding blood-cell uptake was later confirmed true 
for polyamide NV1028 by M.S. student Faten Tamimi working with Dr. G. Davis Harris, Jr. 
and Dr. Puhong Liao, and by parallel work at another contract lab, Ricerca Biosciences 
(Concord, Ohio), where Ricerca worked with radiolabeled NV1028 whose synthesis was 
pioneered in our group by Dr. Puhong Liao.) 
Alternatively, it is possible that polyamide NV1042 is taken up and retained by the 
lung tissue. This phenomenon has been previously described for drugs given 
intravenously (91, 93, 94). The lung serves as a reservoir for exogenous compounds and 
as a pathway for elimination. (This alternative was not supported by later radiolabeling 









Figure 2.5. Representative chromatograms of NV1042. NV1042 in D5W (ECF1025), 
NV1042 in plasma fraction (ECF1033). LC-MS Method: 5-60% ACN/0.1% aq. formic acid 






Binding Studies of TMG Asymmetric Hairpin Polyamides (TMG-AHP) NV1078 and 
NV1087 with Designed, 120 bp DNA Sequences 
3.1 Introduction 
The goal of this work was to determine the binding events that take place in vitro 
between a designed 120 bp DNA and the two large antiviral TMG polyamides, NV1078, 
and NV1087. TMG polyamides contain a modified N-terminus (1, 1, 3, 3 
tetramethylguanidine) (Table 1.1 and 1.2, also Figures 3.4 and 3.5).  The 120 bp DNA 
fragment was designed to eliminate the possibility of superposed or otherwise confused 
binding sites. 
Superposition of multiple binding sites was often observed when large polyamides 
bind to dsDNA and made differentiation among binding sites and determination of all 
associated dissociation constants (Kd) impossible in prior reported work (86). It is 
impossible to tell which binding site corresponds to the calculated Kd since large 
polyamides can bind with high affinity even though the binding sequence is not ideal or 
“correct” according to previously-established binding rules (60).  
Binding events were determined using DNase I footprinting (11, 86) and affinity 
cleavage techniques (95). The binding sites of the polyamides have been analyzed by a 
capillary electrophoresis (CE) procedure (86, 96). The dissociation constants (Kd’s) 
derived from the isotherms of the binding sites were calculated according to Langmuir and 
Hill equations (86, 96, 97) based on assumption that the binding is infinitely cooperative 
for all ligands. 
3.2 Materials and Methods  
3.2.1. Design of the 120 bp DNA Fragments  
The 120 bp DNA sequence was designed to include one “perfect matching site” 
for PA NV1078 (green) and one perfect matching site for PA NV1087 (red) (Table 3.1). 
Binding events have been analyzed for four 120 bp DNA sequences, following systematic 
changes in the DNA fragment at TMG binding sites, or locations, to look for sequence 
preferences (A changed to T, G, and C). The primers (forward and reverse), used in 
polymerase chain reaction (PCR) mutagenesis by overlap extension are presented in 
Table 3.1. The primers extended the 90 bp DNA fragment to 120 bp mutated DNA. The 
primers’ suitability was analyzed with the Mfold Web Server which predicts secondary 
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structure of DNA (or RNA) and can be used for examining the folding possibility or the 
hybridization of the primers.  
 
Table 3.2. Primer pairs that extend the 90 bp DNA to 120 bp DNA. The nucleotide 
segments that overlap with the fluorescently labeled primers are represented in bold. The 
perfect matching site for PA NV1087 is highlighted in red, while green nucleotides show 
the perfect matching site for PA NV1078. 
 
A second PCR reaction used the same nucleotide sequence primers labeled with 
FAM or HEX dyes attached at the 5’ ends, to label the 120 bp DNA with CE-compatible 
fluorescent dye (Table 3.2). 6-FAM specifies the fluorescein dye and HEX designates the 
hexa-chlorofluorescein dye (IDT Coralville, Iowa) 
Table 3.2. Fluorescently labeled primers 
 
Double-stranded oligonucleotides were formed by annealing equimolar amounts 
of complementary single strands by heating at 90 °C for 5 min and cooling the samples to 
ambient temperature in 5 mM potassium phosphate and 50 mM NaCl (pH 7.5). 
The PCR settings for the 90 bp DNA extension were: 95 °C for 3 min followed by 
30 cycles of 95°C for 30 sec. allowing denaturation, 56 °C for 1 min annealing, and 68 °C 
for 1 min extension temperature, in the presence of Taq Polymerase (NEB). The DNA 
fragments were separated using a 1.2 % agarose gel, visualized with ethidium bromide, 
and purified with Qiagen Gel Extraction Kit (Qiagen, Valencia, CA 91355).  
The nucleotide order of the 120 bp DNA fragment was verified by Sanger 
sequencing (USB Affymetrix Thermosequenase) and Maxam-Gilbert sequencing (96, 98).  
For the interpretation of capillary electrophoresis (CE) results and to correctly 
assess the footprinting and affinity cleavage events at the nucleotide level, indexing (size 
calling) was performed for every 120 bp DNA fragment. Therefore, the hydroxyl radical 
cleavage products (99) (which include 3’-phosphate and 3’-phosphoglycolate, with 3’-
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phosphate being the primary cleavage product) produced in the affinity cleavage reactions 
were correlated with Maxam-Gilbert sequencing products (96). The fragments generated 
by DNase I footprinting method (3’-dideoxy ribonucleotide) were associated with the end-
termination Sanger products (96).  
All primers and DNA oligomers were purchased from Integrated DNA 
Technologies, Inc. 
3.2.2 Sanger and Maxam-Gilbert Sequencing 
The DNA sequences used in the study have either a FAM or a HEX dye on the 5’ 
end, therefore the mobility of the fragments in the capillary electrophoresis decrease 
comparing with the mobility of the same DNA fragment missing the dye. Indexing (size 
calling) must be performed for every DNA fragment, to assess the footprinting or cleavage 
events correctly at the nucleotide level (86).  
According to the chemistry of the fragments generated in the sequencing cleavage 
reactions, two different indexing methods were used. 
Sanger (USB) sequencing, the end-termination PCR method, correlates the CE 
nucleotide position to the real position of the nucleotides on DNA fragment generated in 
the DNase I cleavage reactions. (96). 
                      
Figure 3.1 Fragments generated in the DNase I reactions and Sanger sequencing 
(96). 
Maxam-Gilbert Sequencing: in order to correlate the hydroxyl radical cleavage 
products (3’-phosphate or 3’-phosphoglycolate) generated in affinity cleavage reactions 
with the fragment position in the CE, a second indexing that creates similar cleavage 
products is necessary (96). The hydroxyl radical generated by the Fenton reaction 
oxidizes DNA by abstracting hydrogen from the deoxyribose ring (99), causing strand 
cleavage. In the case of 5’-labeled DNA, the hydroxyl radical cleavage products will be 3’-
phosphate or 3’-phosphoglycolate. Fragments with 3’-phosphate are the main species 
generated in this reaction (Figure 3.2). 
In the Maxam-Gilbert method (98), DNA is treated in four different reactions which 
cleave at G, A+G, C, and C+T., depending on reagents and conditions: formic acid 
depurinates the purines (A+G), while dimethylsulfate methylates G (and some A). 
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Pyrimidines (C+T) are hydrolyzed with hydrazine, but addition of NaCl limits this hydrolysis 
only to C.  
Piperidine is then added to cleave the phosphodiester bond where the base has 
been removed and eliminate both phosphates from the sugar.  
                  
Figure 3.2. Fragments generated in  affinity cleavage reactions and Maxam-
Gilbert sequencing (96) . 
The fragments generated via end termination PCR technique have a 3’-dideoxy 
ribonucleotide, and moves slower by CE than the corresponding fragment produced by 
OH radicals, which has the 3’-phosphate end (96). 
3.2.3 Quantitative Deoxyribonuclease I (DNase I) Footprinting  
DNase I footprinting method by capillary electrophoresis (CE) was employed to 
determine the binding affinities of TMG polyamides. The four fluorescently-labeled 120 bp 
DNA segments were used for performing DNase I footprinting titration experiments. 
Double-stranded DNA (500 pM, 200 pM and 50 pM) was incubated in presence TKMC 
buffer (with the following composition: 10 mM Tris, 10 mM KCl, 5 mM MgCl2 and 5 mM 
CaCl2) and 10% final concentration CHAPS (10mM) at 37 °C for 5 hours with polyamides 
in a concentration range from 0.2 nM to 60 nM according with protocols previously 
published (57, 86). The samples were digested with the adjusted amount of RQ1 RNase-
Free DNase I (Promega, Madison, WI) for 5 min at 37 °C and the reactions were quenched 
with 200 mM EDTA. The DNase I digested products, obtained following single hit kinetics 
procedure, were purified with Qiagen PCR purification kit (Qiagen, Valencia, CA) and 
eluted from column with elution buffer (EB, Tris-Cl, pH 8.5) (57).  
The samples were analyzed using an ABI 3730Xl DNA Analyzer using Genescan 
600 LIZ as internal lane standard at DNA Core Facility at the University of Missouri. Data 
were processed using GeneMarker V2.4.0 Software Softgenetics LLC, State Collage, PA. 
For the interpretation of the electropherograms, the DNase I cleavage products were 
correlated with Sanger sequencing results of the same fragments.  
For the quantitative analysis of the electropherograms KaleidaGraph 4.1 software 
as fitted to the Hill and Langmuir isotherms was employed. 
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3.2.4 Affinity Cleavage Assay (AC). Orientation of the TMG-AHP  
The four fluorescently-labeled 120 bp DNA segments were used for performing 
affinity cleavage experiments. In the case of both polyamides, NV1078 and NV1087, 
chelating agent, EDTA, was covalently linked to the C-terminus (primary amine of the Ta 
tail) of the polyamides. The PA-EDTA conjugate was incubated with 0.8 equivalence of 
Fe(NH4)2(SO4)2 to form PA-EDTA-Fe(II) derivatives A volume of 100 μL of 1nM DNA was 
incubated with PA-EDTA-Fe(II) conjugate at concentrations ranging from 5 nM to 100 nM. 
The results were registered for 10, 25 or 100 nM. The reaction mixture contained 10 mM 
Tris, 10mM CHAPS at pH 7.5. The cleavage reaction of the OH radicals formed in a 
Fenton reaction (see results) was initiated, activated by adding 100 mM DTT reducing 
agent (86, 98, 100) for a 4-hour incubation time. The reaction was stopped, and the 
products were purified using Qiagen PCR purification kit.  
The samples were analyzed using an ABI 3730Xl DNA Analyzer using Genescan 
600 LIZ as internal lane standard at DNA Core Facility at the University of Missouri. Data 
were processed with GeneMarker V2.4.0 Software Softgenetics LLC, State Collage, PA. 
For the interpretation of the electropherograms, the hydroxyl radical cleavage products 
were correlated with Maxam-Gilbert sequencing results of the same fragments (see 
sequencing).  
3.3 Results and Discussion. Binding preferences of NV1078 and NV1087 
The sequencing results are included in the tables “Size calling 120 XX1 top strand” 
and “Size calling 120 XX1 bottom strand” where X1=A, T, C, G, for every strand. The 
mutation sites that have to be followed were confirmed as follow: 
For 120 bp XA (ECF2141): On top strand: peak 81.3, corresponding to real position 
88, shows A; On bottom strand: peak 24.4 corresponding to the actual position 88 shows 
T, peak 88.4 corresponding to position 26 shows T. 
For 120 bp XT (ECF3043): On top strand: peak 81, corresponding to real position 
88, shows T; On bottom strand: peak 88.4 corresponding to position 26 shows A. 
For 120 bp XC (ECF2142): On top strand: peak 81, corresponding to real position 
88, shows C; On bottom strand: peak 88.7 corresponding to position 26 shows G. 
For 120 bp XG (ECF2159): On top strand: peak 81.2, corresponding to real 





Figure 3.3.  Example of Sanger (USB) sequencing electropherogram for 120XC 
in FAM channel 
 
Quantitative (DNase I) footprinting assay along with affinity cleavage by capillary 
electrophoresis (CE) was used to assign the TMG binding preferences of NV1078 and 
NV1087 polyamides. Binding events have been analyzed for designed 120 bp DNA 
sequence (see methods) following systematic changes in the DNA fragment at TMG 
binding sites or locations (A changed to T, G, and C) to map and quantify dsDNA-
polyamide interactions. Fluorescently-labeled DNA (5’-FAM at the top strand and 5’-HEX 
for the bottom strand) incubated with varying PA concentrations was used to detect the 
binding locations (DNase I) and the binding orientation (affinity cleavage) of the 
polyamides.  
DNase I is an enzyme that cleaves the phosphodiester backbone of the DNA 
double helix (101) relatively nonspecifically (sometimes AT rich sequences being 
disfavored) (101-103). If no polyamide is bound to the DNA, the digestion will encompass 
the whole fragment. However, if the polyamide is bound to the DNA, that particular region 
will not be nicked as much as the polyamide-free control (86). Therefore, the DNase I 
assay detects DNA-polyamide interactions based on the fact that (reversibly) bound 
polyamide protects DNA from enzymatic cleavage. The assay uses DNase I enzyme that 
cleaves the phosphodiester backbone of the DNA double helix in the presence of divalent 
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cations, introducing single-stranded incisions through hydrolysis of the P–O-C3′ bond 
(101, 102, 104).  
The DNase cleavage pattern of the DNA in the absence of the polyamide is 
compared to the cleavage pattern of the same DNA sequence in the presence of 
increasing concentrations of polyamide (from 0.2 nM to 60 nM). 
The first round of DNase I footprint experiments explored the binding of PA’s to 
500 pM of 120 bp DNA followed by experiments using 200 pM substrate (dsDNA) 
concentration. The electropherograms showed saturation below 5 nM PA. Consequently, 
the PA’s concentration range was lowered from 0, 1, 2, 5, 10, 20, 40, 60 nM to 0, 0.2, 0.3, 
0.5, 1, 2, 5, 10 nM. To maintain the proper equilibrium conditions (ligand excess comparing 
with the substrate concentration; the ligand should be at least five times in excess (97) the 
DNA concentration was dropped to 50 pM. 
The binding measurements were performed after sufficient time (5 hours) to allow 
the system to reach equilibrium. Therefore, the equilibrium dissociation constant (Kd), the 
inverse measure of the affinity of the polyamide to dsDNA, and the Hill coefficients were 
determined in a closed system, under equilibrium conditions. The peak areas (DNase I 
experiments) or heights (AC experiments) of the resulting electropherograms were taken 
into consideration. The peak areas in the protected regions were normalized to a 
neighboring control peak not susceptible to polyamide concentration and plotted as 
fraction bound vs. TMG-AHP concentration (11, 105).  
The electropherogram results were fitted to the Hill (n=1) and Langmuir isotherms 
based on the assumption that the binding is infinitely cooperative for all ligands. From the 
fractional saturation θ (Eq. 1), or fraction bound, where L is the free polyamide 
concentration (97), the apparent dissociation constants, Kds, for the binding sites, and the 
Hill coefficients (n) were determined, and the results are presented in Tables 3.2 and 3.3 
θ = ([L]n/Kdn) / (1 + ([L]n/Kdn))  (Eq.1) 
θ = (Ka [PA]) n /1+ (Ka [PA]) n  (Eq.2) 
KaleidaGraph 4.1 software outputs the results of the processed data in the form of Eq 2. 
The chelating agent, EDTA, was covalently linked to the C-terminus (primary 
amine of the Ta tail) of the polyamides and the complex was ligated to iron (II).  The 
complex cleaves DNA strand near the polyamide C-terminus binding site following binding 
of the polyamide in the minor groove. During the reaction, molecular oxygen is reduced to 
hydrogen peroxide in situ (106), followed by Fenton-type chemistry responsible for the 
production of hydroxyl radicals (107). The hydroxyl radicals generated via Fenton reaction 
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cleaves the DNA strand near the polyamide C-terminus binding site (up to 2, 3 nucleotides 
near the Ta-EDTA end) by abstracting hydrogen (H•) from deoxyribose phosphate in the 
DNA backbone (99) (Figure 3.3).  
Fenton reaction: [Fe (EDTA)]2- + H2O2 → [Fe (EDTA)]- + OH- + •OH 
The affinity cleavage results give information about the orientation of the 
polyamides. Hairpin PAs align to adjacent DNA strand in two different ways. N-terminus 
(TMG) to C terminus (3, 3-diamino-N-methyldiproprylamine: Ta) parallel to the 5’-3’ 
direction of the adjacent DNA strand, as shown in Figures 3.4A and 3.5A, called forward 
binding, or N to C terminus parallel to the 3’-5’ direction, as shown in Figures 3.4B and 
3.5B, called reverse binding.  
              
                  A                                                               B 
Figure 3.4. The structure of hairpin TMG NV1078 polyamide and the code of DNA 
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding models: 
filled circles represent imidazole rings; open circles represent pyrrole rings; curves-linking 
circles represent γ-aminobutyric acid; diamonds represent β-alanine; the triangle 
represents TMG. (A) Forward binding, (B) reverse binding. 
 
            
                       A                                                                     B 
Figure 3.5. The structure of hairpin TMG NV1087 polyamide and the code of DNA 
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding models: 
filled circles represent imidazole rings; open circles represent pyrrole rings; curves-linking 
circles represent γ-aminobutyric acid; diamonds represent β-alanine; the triangle 
represents TMG. (A) Forward binding, (B) reverse binding. 
When the polyamides align to a sequence suggested by the recognition rules 
defined by Dervan (54, 60) as in Figures 3.4 and 3.5, the binding site is considered a 
perfect match site. The mismatched sites are the sites where the polyamide aligns to a 
DNA sequence that is different. For example, a guanine (G) or a cytosine (C) appears in 
the place of A or T or imidazole aligns to a nucleotide that is different than G. 
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The binding affinity of PA and PA-EDTA conjugates is similar as demonstrated in 
the binding study of PA1 (11). The conjugated EDTA group removes one positive charge 
and adds three negative charges to the polyamide when not bound by Fe(II) (11). 
3.3.1 Binding preferences of NV1078  
The Map in Figure 3.6 presents the 120bp DNA sequence and the variety of 
possibilities of polyamide NV1078 to bind in the minor groove of the ds DNA. The cleavage 
pattern of the control samples can be compared with the cleavage pattern of the sample 
treated with 0.5 nM NV1078. The affinity cleavage sites are depicted with the help of the 
vertical arrows, while and related electropherograms display the DNase I protection sites. 
The data represents the interpretation of the following experiments: DNase I 
Footprinting of 50 pM DNA (ECF3011, ECF3018, ECF3030, ECF3058); Sequencing with 
USB Kit (ECF2142); Affinity cleavage: 1 nM DNA and 25 nM NV1078 (ECF3037); Maxam-
Gilbert Sequencing (ECF2135). 
 
Figure 3.6. Map of 120 XC bp DNA. The first two electropherograms provide 
information for the top DNA strand, labeled at 5’ with FAM dye. The electropherograms in 
the HEX channel correspond to the mirror image of the bottom nucleotide strand. 
Nucleotides marked in red are the integration sites, were the dissociation constant values 
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Kd’s were determined. The regions outside the boxes the protected areas were NV1078 
binds with high affinity. 
  
The data gathered from electropherograms have been used to calculate the 
apparent fractional saturation θ (the fraction of polyamide bound to the DNA). The 
isotherms, fraction bound vs. polyamide concentration, allow the calculation of 
association/dissociation constants and Hill coefficient.  
For the integration site, the fraction bound was calculated as in Eq.3, where Isite 
represents the fluorescence intensity, the peak height in a footprint region, and Iref is the 
peak height of a reference site that does not change in intensity during titration. I0 and I0ref, 
as in Eq.4, are the intensities of the sample peak and reference peak in the control 
samples (just DNA cut by DNase I or hydroxyl radicals, without polyamide treatment). To 
obtain the apparent fractional saturation, θ, the results were normalized to one. 
 
Θ = Isite /Iref;  (Eq.3) 
Θ0 =I0site/I0ref   (Eq.4) 
Θapp =1-Θ/Θ0   (Eq.5) 
 
Figure 3.7. Isotherm (KaleidaGraph 4.1 software). Results according with 
Langmuir equation (upper table) and Hill equation (lower table) of 120 bp DNA, [DNA] = 
50 pM, incubated with NV1078 (0 - 10 nM) and digested with 0.35 U DNase I.  
 
The results derived from Hill equation (Eq.2) in this particular case (Figure 3.7) are:  
Kd = 1/3.5 = 0.74 nM; Hill coefficient, n = 1 
From the cumulative DNase I and affinity cleavage data on the 120bp DNA, three 
binding sites for TMG-AHP NV1078 were identified. The dissociation constants have been 
calculated from the isotherms obtained in at least three independent experiments. The 
detailed results are presented in the appendix and in the supplementary material. 
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(Appendix 1: Dissociation/association constants: NV1078 & 120 bp 50 pM DNA; Figure 
3.11: Isotherm triplicates: NV1078 120 bp, 50 pM DNA). 
 
 
 Table 3.2. Summary of Hill dissociation constants for four binding sites on 120XA, 




Table 3.3. Summary of Hill association constants for four binding sites on 120XA, 




The first binding site, not influenced by mutations (pos. 27-39, 1) in Figure 3.6, is 
a forward binding site where NV1078 tolerates well two mismatched (mm) nucleotides. 
The high cooperativity at this location shows that an alternative binding mode is also 
probable at this site, namely a two-mm forward (29-41) site, not supported by AC sites, 
where the tail binds TATT, TMG at T.  
Binding site no. 2 (pos. 59-71), Figure 3.6, holds the potential for superposition of 
different binding sites. This site can be associated with a forward 0-mm binding (2a, 
5’TGTAATATGTTTT3’) or a 0-mm reverse fashion (2c, 5’TTTTGTAAATTCT3’). This 
binding site is not affected by mutations and shows a nearly constant Kd (Appendix 1). 
The affinity cleavage patterns suggest that 0-mm reverse binding is preferred over forward 
binding.  
According to the dissociation constant values for the third binding site Figure 3.6, 
3 (position 85-97), the location with systematic changes in the DNA fragment at TMG 
binding sites, shows preference for C and T (Table 3.2, Fig. 3.8). The presence of G is 





Figure 3.8.  Dissociation constants for the binding sites on 120 bp DNA of NV1078, 
based on Table 3.2 
  
3.3.2 Binding preferences of NV1087 
The dissociation constants have been calculated from the isotherms obtained in at 
least three independent experiments. The detailed results are presented in the appendix. 
(Appendix 2: KaleidaGraph data NV1087 for 120 bp DNA at 50 pM;), Table 3.4, Figure 
3.9., and Figure 3.12 (KaleidaGraph Isotherms NV1087 120 bp).  
The binding profile of NV1087 on the same 120 bp DNA sequence revealed four 
binding sites. Binding of NV1087 in site no.1 (position 24-37), the position with systematic 
changes in the DNA fragment at TMG binding sites, derived from dissociation constant 
values, shows a preference for C, T, and A (Table 3.4, Fig. 3.5). Binding site no. 2 
(position 55-68) one mm forward binding site is not affected by mutations. Binding site no. 
3 (position 66-79) one mismatch reverse binding site is not affected by mutations and is 
also the most tightly bound site. Binding site no. 4 (position 87-100), 2mm reverse binding 
site is not affected by mutations. 
Table 3.4.  Summary of Kd values obtained for NV1087. The polyamide tail binding 













































SUMMARY  OF THE HILL DISSOCIATION 
CONSTANTS FOR THE BINDING SITES ON 120 BP 
DNA OF NV1078






Figure 3.9.  Dissociation constants for the binding sites on 120 bp DNA of NV1087 
based on Table 3.4. 
 
 
Figure 3.10. Binding of NV1087 in position #1, the position with systematic 
changes in the DNA fragment at TMG binding or location sites derived from association 
constant values, the probability plot shows preference for C, T, and A. (WebLogo 3.4) 
 
3.4 Conclusion 
The goal of this work was to provide a detailed binding site analysis illustrating how 
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SUMMARY  OF THE HILL DISSOCIATION CONSTANTS 
FOR THE BINDING SITES ON 120 BP DNA OF NV1087
KdHill (nM) A KdHill (nM) T KdHill (nM) C KdHill (nM) G
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second aim was to determine how the DNA sequence where the polyamide tail binds can 
influence the binding affinity. 
In the AC experiments, all significant binding sites appeared at 10 nM PA and 
became clearer at 25 nM PA. Indexing (size calling) of the electropherograms was 
achieved with Sanger and Maxam-Gilbert sequencing (11). The 3’ shift between the 
forward and revers strands characteristic for minor groove binders (108) was observed. 
Although reverse orientation is considered less favorable for small polyamides (109), such 
patterns are seen for large polyamides in association with the specified DNA fragment. 
Reverse binding was detected in the present work and also in recent studies of my 
colleagues  (11, 86, 105).  
The results for NV1078 show very tight binding for the forward perfect-binding site 
(Kd = 0.23-0.7 nM), the highest value being registered when TMG binds G, or is located 
next to G (Table 3.2 and Figure 3.8, binding site #3). However, the reverse perfect match 
site when TMG binds to T presents the same low value (at site #2). Site #1, a two-
mismatch forward-binding site is independent of mutations, having similar Kd values of 
about 0.3 nM in every strand (TMG at A). 
Polyamide NV1087 binds in four different sites (Table 3.4). The forward, perfect-
binding site presents slightly higher Kd values when TMG binds to G. One-mismatch 
reverse (TMG at A) has the lowest Kd (0.2 nM), very close to one-mismatch forward (0.4 
nM) (TMG at A). 
The binding of the polyamides is influenced not just by the nucleotide position at 
the TMG site but also by the entire nucleotide sequence at the tail of the polyamides. If 
the polyamides tail bind to A, T, or C, the binding affinity is increased. The presence of G 





3.5 Supplementary material 
Figure 3.11: Isotherm triplicates of 3 binding sites of NV1078 on 4 DNA sequences. (120 













Figure 3. 12: Isotherm triplicates of 4 binding sites of NV1087 on 4 DNA sequences. (120 











Interactions Between two TMG Asymmetric Hairpin Polyamides (TMG-AHP), 
NV1078 and NV1087, with the HPV16,18 LCR segment 
 4.1Abstract 
Long-term, persistent infection with high-risk strains of human papillomavirus 
(HPV) is the precursor of most of the cervical carcinomas and an increasing number of 
oropharyngeal squamous cell carcinomas which represent 90-95% of head and neck 
cancers (3). While the vaccines can protect the targeted population of possible infections 
(4), no HPV antiviral drugs are available for the definitive treatment of preexisting or future 
viral infections. To treat current or future HPV infections, drugs that selectively block virus-
specific processes, but do not damage the host cells, are needed. 
The antiviral compounds employed in the present study, NV1078 and NV1087, 
represent a subclass of the heterocyclic oligomers known as N-methylpyrrole N-
methylimidazole (Py-Im) polyamides (PAs).  They have a modified N-terminus capping 
group, 1,1,3,3 tetramethylguanidine (TMG) and an asymmetric structure (26), and will be 
referred to as TMG-AHPs for TMG-Asymmetric Hairpin Polyamides. It has been 
demonstrated (Edwards, T. and Fisher, C.) that the two compounds possess the unique 
property of unusual antiviral activity against three high-risk HPV strains (HPV16, HPV18, 
and HPV31) (Table 1). The antiviral compounds eliminate the viral load of infected 
keratinocytes without integration of the viral DNA episomes in the host chromosome. The 
TMG-AHPs are analogs of natural products Distamycin A and Netropsin that function, as 
has been recently determined (5, 6), by interfering with natural virus-host interactions and 
by stimulating the host cell’s DNA Damage Response to destroy viral DNA. 
The interactions between the aforementioned polyamides and LCR of viral HPV16 
and HPV18 DNA fragments were studied to determine the DNA sequence specificity and 
binding sites of the polyamides, to help establish the TMG-AHP’s mechanism of action. 
The quantitative deoxyribonuclease I (DNase I) footprinting method was used (11, 97), 
along with affinity cleavage assays (95), to map and measure the interactions between 
fluorescently labeled DNA and the active TMG-AHPs. The dsDNA-AHPs binding locations 
were detected and quantified by capillary electrophoresis (110). 
Results in this chapter demonstrate that TMG-AHPs 1078 and 1087 recognize 13 
nucleotides, and bind with nanomolar affinity to the expected binding sites, as well as one-
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, two-, and even three-mismatch (sites of polyamide binding with a DNA sequence 
containing one or more bases that do not correspond to the expected polyamide binding 
sequence) binding sites. Moreover, it was observed that the asymmetric polyamides 
(APAs) have a conclusive preference for the region adjacent and overlapping with E1 and 
E2 viral proteins binding sites, where both polyamides bind in a cluster. The data indicate 
that viral replication for HPV could be disturbed by TMG-AHPs binding at numerous sites 
with high affinity for the sequence (7880-30) of the HPV16 viral LCR DNA or the preferred 
binding region of HPV18 LCR (7841-43).  
4.2 Introduction 
Although human papillomavirus (HPV) vaccines have been developed (4), the 
occurrence of HPV infections is still extremely prevalent. To treat the already existent or 
future viral infections, drugs that selectively block virus-specific processes but do not 
damage the host cells are needed. Persistent infection causes genomic instability and 
eventually the integration of the viral genome into the host chromosomes (111, 112), and 
is the main reason for neoplasia and cancer. The elimination of viral DNA during the 
maintenance stage of a persistent infection is the strategy behind the discovery of the 
antiviral compounds described here.  
The genetic information of Human Papillomaviruses is stored in small, 
chromatinized circular dsDNA viral genome (episome) that typically contains 8 genes (27). 
The HPV genome is approximately 8000 base pairs long. Since the viral genome does not 
encode any polymerases, the only viral enzyme being E1 (an NTPase / helicase), the 
maintenance of viral load depends on the host, infected keratinocyte cells’ replication 
machinery. Two viral proteins E1 and E2 also have decisive roles in most replication 
pathways. These viral proteins recruit host proteins, including DNA polymerase alpha and 
many proteins which are part of the DNA Damage Response (DDR) defense mechanism 
(8, 9, 15, 48, 113, 114), to initiate and enable the replication process. Also, these viral 
proteins may serve as bridges between the viral genome and the cellular chromatin (36), 
ensuring participation of the viral proteins to the replication process. It is important to 
mention that opposing many studies supporting the importance of E1 and E2 in the viral 
lifecycle, it was also shown (using various transfected cell lines) that a different  replication 
mechanism, independent of viral trans-factors, E1 and E2 (115), is also possible. HPV 
DNA is capable of replicating by either random choice or a once-per-S-phase mechanism, 
depending on cell type and levels of E1 protein (33). In the particular case of W12E cells, 
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a once-per-S-phase replication mechanism, dependent on E1 and E2, is most frequently 
observed (116).    
Previous studies (10-12, 112, 117) have shown that viral dsDNA can be targeted 
using small molecules such as pyrrole-imidazole polyamides, homologs of natural 
products Distamycin A and Netropsin (49). To overcome the high toxicity but maintain 
antiviral properties of the minor groove binders Distamycin A and Netropsin, hairpin N-
methylpyrrole-N-methylimidazole (Py-Im) polyamides (PAs) were designed (54, 60). To 
exert their effect, the polyamides have to reach and bind to their cellular target, the viral 
dsDNA in the nuclei. Slight, sometimes minimal structural changes of the compounds may 
result in distinct cellular or nuclear distribution with dramatic changes of biological activity. 
Efficient cellular uptake of hairpin PAs was observed in human keratinocytes harboring 
high-risk HPV episomes (5, 6, 10). Hairpin polyamides specifically recognize and bind with 
high (nanomolar) affinity to dsDNA in minor groove regions by hydrogen-bonds (Fig.1) 
(49, 59). The binding of PAs is followed by alterations of the dsDNA shape by widening 
the minor grove, narrowing the major groove (54, 60), and stiffening the double helix 
(61).The introduction of β-alanine building blocks confer additional flexibility for the 
molecules and permit a better mimic of the DNA curvature (55, 57). By binding with high 
affinity in the minor groove, polyamides displace proteins from DNA, interfering with 
natural processes (62) and acting as transcriptional activators or repressors.  
To decrease or eliminate the HPV viral DNA (episomes) from infected keratinocyte 
cells, a library of more than 100 polyamides was synthesized. It was found that some of 
the long hairpin polyamides are active against high-risk HPV strains (HPV16, HPV18, or 
HPV31) (5, 6, 10-12, 26) and cause a substantial decrease of the HPV DNA episome 
levels, eradicating the viral load (amount of viral DNA per cell) in undifferentiated 
keratinocyte monolayers, in the absence of integration of viral DNA (5, 6, 117). A minimum 
of 10 DNA base-pair coverage is necessary for viral activity (10). 
Among the newly synthesized polyamides (work by Kevin J. Koeller, G. Davis 
Harris. Jr.), two stand out as having the greatest antiviral activity against three high-risk 
HPV strains: HPV16, HPV18, and HPV31 (26) (Table 4.1). The two polyamides employed 
in the present study, NV1078 and NV1087, have a modified N-terminus capping group, 
1,1,3,3 tetramethylguanidine (TMG) and an asymmetric hairpin structure (TMG-AHP). 
These distinct polyamides have the ability to decrease HPV16, 18, and 31 episome levels 
in undifferentiated W12E cell monolayers and tissue culture, in the absence of integration 
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of viral DNA, with greater efficacy than NV1042, the most potent compound published, 
considered the lead compound (work by Terri G. Edwards, NanoVir LLC). 
The interactions between the above-mentioned polyamides and LCR of viral 
HPV16 and HPV18 DNA fragments were studied to determine the DNA sequence 
specificity and binding sites of the polyamides, to help establish the TMG-AHP’s 
mechanism of action. The studied DNA sequence includes the core replication origin 
containing the cis-elements (which do not code for proteins or RNA) imperative in the 
process of DNA replication: one E1 protein binding sequence, and the three important E2 
binding sites (E2BS1, E2BS2, and E2BS3) (118). The E1BS for HPV16 sometimes 
referred to as the origin-binding domain (OBD), is an 18 base-pair sequence: 
5’ATAATACTAAACTACAAT3’ (HPV16 episome sequence: 7895-8). The DNA fragment 
also contains A/T rich regions surrounding the E1BS and E2BSs and transcription factor 
binding sites. 
 
4.2 Methods  
The methods used in this work were DNase I footprinting to determine the binding 
affinities of the TMG polyamides and the affinity cleavage assay (AC) to ascertain the 
orientation of the TMG-AH polyamides. A detailed description of the methods is provided 
in Chapter 3. 
In addition, the HPV16 LCR  7662-122 bp fragment was generated by Polymerase 
Chain Reaction (PCR). The primers employed in reaction were: (forward) 5’-FAM-TAA 
ATC ACTATG CGC CAA CGC-3’ and (reverse) 5’-HEX-CCT GTG GGT CCT GAA ACA 
TTG-3’. All oligonucleotides were obtained from IDT (Coralville, Iowa). 
4.3 Results 
The polyamide NV1078 has the following composition: TMG-
PβPPImβPPβγPPβPPPβPPPβTa, where Im represents N-methylimidazole, Py stands for 
N-methylpyrrole, β–alanine, γ is γ-aminobutyric acid, and Ta represents 
CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-methyldipropylamine. NV1078 is present in 
solution as a TFA salt. According to the published pairing rules (54, 60) the perfect binding 
site for NV1078 will be: 5’-XXXWWWWGWWWW-3’ where W=A or T, and X stands for 
the unknown nucleotides for TMG binding. The hairpin structure and the mode of binding 







               
(a)                                                              (b) 
Figure 4.1. The structure of hairpin TMG NV1078 polyamide and the code of DNA 
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding 
models: filled circles represent imidazole rings; open circles represent pyrrole rings; 
curves-linking circles represent γ-aminobutyric acid; diamonds represent β-alanine; the 
triangle represents TMG. (A) Forward binding corresponds to N to C/5’ to 3’ 
orientation, while reverse binding (B) corresponds to N to C/3’ to 5’ direction. 
 
The polyamide NV1087 has the following structure: TMG-
PPPβPPβPImγPβPPβPPPβPβTa, where Im represents N-methylimidazole, Py stands for 
N-methylpyrrole, β is β–alanine, γ is γ-aminobutyric acid, and Ta represents 
CH3N(CH2CH2CH2NH2)2 or 3,3’-diamino-N-methyldipropylamine. According to the pairing 
rules (54, 60) the perfect forward binding site for NV1087 will be: 5’ X-X-X-W-W-W-W-W-
W-W-W-G-W 3’ where W=A or T, and X stands for the unknown nucleotide for TMG 
binding (Figure 4.2). 
 
             
 
                        (a)                                                                    (b) 
Figure 4.2. The structure of hairpin TMG NV1087 polyamide and the code of DNA 
recognition upon binding to DNA (W: A or T; X, Y: unknown nucleotides). Binding 
models: filled circles represent imidazole rings; open circles represent pyrrole rings; 
curves-linking circles represent γ-aminobutyric acid; diamonds represent β-alanine; the 
triangle represents TMG. (A) Forward binding corresponds to N to C/5’ to 3’ 





4.4.1 NV1078 polyamide binding sites on 365 bp natural HPV16 (7662-122) 
sequence  
The first goal of this study was to provide a detailed binding site analysis, 
illustrating the binding ability of polyamide NV1078 to the specified DNA sequence. The 
HPV16 LCR (GeneBank AF125673.1LCR) region contains cis-acting elements that 
regulate transcription and replication of viral DNA (118).  
The studied DNA sequence 7662-122 includes one E1 protein binding sequence, 
and the three essential E2 binding sites: E2BS1 (35-46), E2BS2 (50-61), and E2BS3 
(7858-7869), as shown by the green boxes (Figure 4.3). The E1BS for HPV16, referred 
to as the origin-binding domain (OBD), is an 18 base-pair sequence: 
5’ATAATACTAAACTACAAT3’ (HPV16 episome sequence: 7895-8) (27). The DNA 
fragment also contains A/T rich regions surrounding the E1BS and E2BSs and 
transcription factor binding sites (SP1, TATA motif).  
The binding of E2 viral protein to its binding sites and recruitment of E1 viral protein 
to form a double hexamer is fundamental to viral DNA replication (119). The mapping 
studies based on data gathered from the DNase I and affinity cleavage experiments 
indicate that the polyamide NV1078 binds with high affinity to multiple sites adjacent to 
and overlapping with the E1BS and E2BSs.  
The binding information is presented in the ECF3097 Map (Figure 4.3) as well as 




Figure 4.3. Binding sites of NV1078 on 365 bp LCR HPV16 fragment. Horizontal 
arrows depicting the binding sites are color coded.  Black arrow shows perfect binding 
site; Red arrow - single mismatch (mm) site; Purple arrow - double mm; Blue arrow - triple 
mm; Green arrow - quadruple mm; Solid arrow - forward fashion of PA binding; Dashes 
arrow - reverse fashion of PA binding; Green boxes show E2 binding sites; Red letters 
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represent the integration peaks; Blue or green letters represent the reference peaks. Red 
numbers show the dissociation constant values Kd [nM] presented in Table 4.2. The 
yellow background highlights the footprinting regions. Red AC sites are present just at 
high polyamide concentrations (100 nM). 
 
A total of 16 binding sites were identified according to the affinity cleavage 
patterns. The binding sites and the corresponding nucleotide sequences are presented in 
the Tables 1 and 2. The affinity cleavage patterns (vertical arrows) indicate the position of 
the PA tail (Figures 4.3) where the hydroxyl radicals are formed (Chapter 3).  
The hydroxyl radical cleavage pattern provides information about the PA binding 
site and the orientation (forward or reverse) as described above. Horizontal arrows show 
the polyamide binding sites, which may only be occupied by a single polyamide molecule 
at a time. The length of the arrow corresponds to the DNA sequence to which the 
polyamide is bound, while the arrow color coding relates to the literature binding rules. 
The binding of the polyamides in the minor groove is an equilibrium process.  
The polyamide associates and dissociates from the minor groove and rapidly 
rebinds in an alternative way if possible, resulting in a variety of binding patterns. The 
majority of the sites permit alternative binding modes. Also, overlapping binding sites are 





Table 4.1.   Binding sites of TMG-AHP, NV1078 on HPV16 (7662-122) fragment. The 13 
nucleotide binding sequence of the polyamide has been shown with the associated 5 
nucleotide flanking sequences. Blue letters indicate the TMG binding site and the 














0 GGCAC-ATATTTTTGGCTT-GTTTT 2 7705-7717 forward  ATAT 
0 GCACA-TATTTTTGGCTTG-TTTTA 3 7706-7718 forward TATT 
0 TTTAA-ACAAGCCAAAAAT-ATGTA 3 7707-7719 reverse (BS) AAAT 
1 ATTAG-GTTAGTTAAAACA-AGCCA 1 7717-7729 reverse (BS) AACA 
1 GGCTT-GTTTTAACTAACC-TAATT 4 7718-7730 forward GTTT 
1 AATTA-GGTTAGTTAAAAC-AAGCC 4 7718-7730 reverse (BS) AAAC 
2 ATGCA-ATTAGGTTAGTTA-AAACA 1 7722-7734 reverse (BS) GTTA 
2 TTTTA-ACTAACCTAATTG-CATAT 4 7723-7735 forward ACTA 
2 ATATG-CAATTAGGTTAGT-TAAAA 4 7723-7735 reverse (BS) TAGT 
2 TTAGT-TAAAACAAGCCAA-AAATA 3 7711-7723 forward (BS) TAAA 
3 TGCAA-TTAGGTTAGTTAA-AACAA 1 7721-7733 forward (BS) TTAG 
3 AAATA-TGCAATTAGGTTA-GTTAA 1 7726-7738 forward (BS) TGCA 
3 AATTG-CATATTTGGCATA-AGGTT 2 7737-7749 forward  CATA 
4 TTATG-CCAAATATGCAAT-TAGGT 1 7733-7745 forward (BS) CCAA 
4 AACCT-AATTGCATATTTG-GCATA 1 7731-7743 reverse TTTG 
4 TATTT-GGCATAAGGTTTA-AACTT 1 7744-7756 forward  GGCA 
5 TGGCA-TAAGGTTTAAACT-TCTAA 1 7748-7760 reverse AACT 
5 ATTTA-GTTGGCCTTAGAA-GTTTA 4 7760-7772 reverse (BS) AGAA 
6 AGGGT-GACATTTAGTTGG-CCTTA 2 7768-7780 forward (BS) GACA 
6 AAATG-TCACCCTAGTTCA-TACAT 4 7779-7791 forward TCAC 
7a ACATG-AACTGTGTAAAGG-TTAGT 4 7798-7810 reverse AAGG 
7a ATGAA-CAATGTATGACTA-ACCTT 2 7812-7824 reverse (BS) ACTA 
7b TGTGT-AAAGGTTAGTCAT-ACATT 1 7806-7818 reverse TCAT 
7b TTTAC-AAATGAACAATGT-ATGAC 1 7819-7831 reverse (BS) ATGT 
7c ACAAA-TGAACAATGTATG-ACTAA 2 7816-7828 forward (BS) TGAA 
7c ACATT-GTTCATTTGTAAA-ACTGC 0 7824-7836 forward GTTC 
8 TGTTC-ATTTGTAAAACTG-CACAT 0 7828-7840 reverse ACTG 
9 GCAAA-CCGTTTTGGGTTA-CACAT 2 7859-7871 forward CCGT 















10 GTAAC-CCAAAACGGTTTG-CACAC 3 7855-7867 forward (BS) CCAA 
10 CTTGT-AAATGTGTAACCC-AAAAC 1 7866-7878 reverse (BS) ACCC 
11a ATATA-AGTTGCTTGTAAA-TGTGT 2 7876-7888 forward (BS) AGTT 
11a AAGCA-ACTTATATAATA-ATACT 1 7886-8898 forward  ACTT 
11b TGTAG-TTTAGTATTATTA-TATAA 0 7893-1 reverse (BS) ATTA 
12 TTATT-GTAGTTTAGTATT-ATTAT 0 7897-5 forward (BS) GTAG 
12 TTATA-TAATAATACTAAA-CTACA 2 7893-1 reverse TAAA 
12 ACTAA-ACTACAATAATTC-ATGT 3 1-13 forward ACTA 
13 TAAAC-TACAATAATTCAT-GTATA 2 3-15 reverse TCAT 
13 TACAT-GAATTATTGTAGT-TTAGT 1 1-13 forward (BS) GAAT 
13 ACGCC-CTTAGTTTTATAC-ATGAA 1 16-28 reverse (BS) ATAC 
14 ATAAT-TCATGTATAAAAC-TAAGG 1 12-24 reverse AAAC 
14 TACGC-CCTTAGTTTTATA-CATGA 2 17-19 forward (BS) CCTT 
14 TCATG-TATAAAACTAAGG-GCGTA 2 17-29 reverse AAGG 
14 ATTCA-TGTATAAAACTAA-GGGCG 2 17-29 reverse CTAA 
14 TAAGG-GCGTAACCGAAAT-CGGTT 2 30-42 forward GCGT 
15 GGTTG-AACCGAAACCGGT-TAGTA 3 49-61 reverse CGGT 
15 ACCGG-TTAGTATAAAAGC-AGACA 3 61-73 forward TTAG 
15 TGTCT-GCTTTTATACTAA-CCGGT 3 61-73 reverse (BS) CTAA 
15 ATGTC-TGCTTTTATACTA-ACCGG 3 62-74 reverse (BS) ACTA 
15 CCGGT-TAGTATAAAAGCA-GACAT 3 62-74 forward TAGT 
16 TGGTG-CATAAAATGTCTG-CTTTT 2 73-85 forward (BS) CATA 
16 TTATG-CACCAAAAGAGAA-CTGCA 1 86-98 forward  CACC 
 
In Table 4.1, all binding sites of NV1078 on the HPV16 (7662-122) fragment are 
shown.  The 13 nucleotide binding sequence of the polyamide has been shown with the 
associated 5 nucleotide flanking sequences. Blue letters in the DNA sequence indicate 
the binding site of TMG, and the highlighted guanine (G) shows an imidazole binding site. 
Considering the best fit to the affinity cleavage patterns and the lowest mismatch number 
the most probable orientations of the NV1078 polyamide (derived from Table 4.1) are 




Table 4.2. Considering the best fit to the affinity cleavage patterns and the lowest 
mismatch number the most probable orientations of the NV1078 polyamide (derived from 











1 ATTAG-GTTAGTTAAAACA-AGCCA 1 7717-7729 reverse (BS) 1.18 0.8 
2 ATGCA-ATTAGGTTAGTTA-AAACA 1 7722-7734 reverse (BS) nd nd 
3 AAATA-TGCAATTAGGTTA-GTTAA 1 7726-7738 forward (BS) 2.59 0.4 
5 TGGCA-TAAGGTTTAAACT-TCTAA 1 7748-7760 reverse 2.1 0.5 
7a ATGAA-CAATGTATGACTA-ACCTT 2 7812-7824 reverse (BS) 5.05 0.2 
7b TGTGT-AAAGGTTAGTCAT-ACATT 1 7806-7818 reverse 2.5 0.4 
8 TGTTC-ATTTGTAAAACTG-CACAT 0 7828-7840 reverse 1.98 0.5 
11a AAGCA-ACTTATATAATA-ATACT 1 7886-8898 forward nd nd 
11b TGTAG-TTTAGTATTATTA-TATAA 0 7893-1 reverse (BS) 1.9 0.5 
12 TTATA-TAATAATACTAAA-CTACA 2 7893-1 reverse 2.2 0.5 
13 TACAT-GAATTATTGTAGT-TTAGT 1 1-13 forward (BS) 3.3 0.3 
 
The presence of G nucleotide in the tail binding sequence increases the value of 
Kd (compare site # 1 with sites # 3, # 8, and # 13).  The Kd values not always rise with 
the increasing number of mismatch nucleotides as shown in Figure 4.4.   
 
Figure 4.4. Binding affinity of NV1078 on HPV16 LCR sequence 




The map ECF3097NV1087(2) Figure 4.5, of DNase I footprinting and affinity 
cleavage experimental results of NV1087 polyamide binding sites on 365 bp natural 
HPV16 sequence reveal 13 binding sites. The blue box indicates the E1 protein binding 
site while E2 binding sites are delineated by green boxes. Multiple cleavage patterns stand 
out in the region 7881-17.  
 
Figure 4.5. Binding sites of NV1087 on 365 bp LCR HPV16 fragment. Horizontal 
arrows depicting the binding sites are color coded.  Black arrow shows perfect binding 
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site; Red arrow - single mismatch (mm) site; Purple arrow - double mm; Blue arrow - triple 
mm; Green arrow - quadruple mm; Solid arrow - forward fashion of PA binding; Dashes 
arrow - reverse fashion of PA binding; Green boxes show E2 binding sites; Red letters 
represent the integration peaks; Blue or green letters represent the reference peaks. Red 
numbers show the dissociation constant values Kd [nM] presented in Table 4.4. The 
yellow background highlights the footprinting regions. 
 
 
Table 4.3.   Binding sites of TMG-HAP, NV1087 on HPV16 (7662-122) fragment. 
The 13 nucleotide binding sequence of the polyamide has been shown with the associated 
5 nucleotide flanking sequences. Blue letters indicate the TMG binding site and the 














0a ACCGC-TGTTAGGCACATA-TTTTT 4 7695-7707 reverse  ATA 
0b AAACA-AGCCAAAAATATG-TGCCT 2 7704-7726 reverse (BS) ATG 
0c CACAT-ATTTTTGGCTTGT-TTTAA 3 7707-7729 forward ATT 
1a TGGCT-TGTTTTAACTAAC-CTAAT 1 7717-7729 reverse  AAC 
1b AACTA-ACCTAATTGCATA-TTTGG 3 7728-7740 forward ACC 
1c CCAAA-TATGCAATTAGGT-TAGTT 3 7728-7740 reverse (BS) GGT 
1'a TAACC-TAATTGCATATTT-GGCAT 3 7731-7743 forward TAA 
1'b ATGCC-AAATATGCAATTA-GGTTA 3 7731-7743 reverse (BS) TTA 
2 GCCTT-AGTTGTTTAAACC-TTATA 1 7751-7763 reverse (BS) ACC 
2'a TTGGC-CTTAGAAGTTTAA-ACCTT 3 7754-7766 forward (BS) CTT 
2'b AAGGT-TTAAACTTCTAAG-GCCAA 3 7754-7766 reverse  AAG 
2'c CTAAG-GCCAACTAAATGT-CACCC 1 7767-7779 forward  GCC 
3a AATGA-ATGACTAACCTTT-ACATT 4 7806-7818 forward (BS) ATG 
3a' TGTGT-AAAGGTTAGTCAT-ACATT 4 7806-7818 reverse CAT 
3b TTACA-AATGAACAATGTA-TGACT 3 7818-7830 reverse (BS) GTA 
3b' AGTCA-TACATTGTTCATT-TGTAA 3 7818-7830 forward TAC 
4 GTGCA-GTTTTACAAATGA-ACAAT 1 7826-7839 forward (BS) GTT 
5a GCAAC-TTATATAATAATA-CTAAA 1 7888-7890 forward TTA 
5a' TTTAG-TATTATTATATAA-GTTGC 1 7888-7890 reverse (BS) TAA 
6 TATTA-TTATATAAGTTGC-TTGTA 2 7883-7895 forward (BS) TTA 
7a TAGTA-TTATTATATAAGT-TGCTT 0 7886-7898 forward (BS) TTA 
7b GCAAC-TTATATAATAATA-CTAAA 1 7888-7890 reverse ATA 
7b' TTTAG-TATTATTATATAA-GTTGC 1 7888-7890 forward (BS) TAT 
8a TATAT-AATAATACTAAAC-TACAA 1 7894-2 reverse AAC 











8b ATACA-TGAATTATTGTAG-TTTAG 1 2-14 reverse (BS) TAG 
9a TACAT-GAATTATTGTAGT-TTAGT 1 1-13 forward (BS) GAA 
9b CCCTT-AGTTTTATACATG-AATTA 1 12-25 reverse (BS) TGA 
10 ATTCA-TGTATAAAACTAA-GGGCG 1 15-27 reverse TAA 
11a ACCGG-TTAGTATAAAAGC-AGACA 2 61-73 forward TTA 
11b ATGTC-TGCTTTTATACTA-ACCGG 1 62-74 reverse (BS) CTA 
12a CGGTT-AGTATAAAAGCAG-ACATT  1 63-75 reverse CAG 
12b TTTGG-TGCATAAAATGTC-TGCTT 1 75-87 reverse (BS) GTC 
13a AAAGC-AGACATTTTATGC-ACCAA 1 74-86 reverse TGC 
13b TTTAT-GCACCAAAAGAGA-ACTGC 3 85-97 forward GCA 
 
 
In Table 4.3, all binding sites of NV1087 on the HPV16 (7662-122) fragment are 
presented. Considering the best fit to the affinity cleavage patterns and the lowest 
mismatch number of the DNA sequence according to the binding rules, the most probable 


















Table 4.4.  The most probable binding sequences of NV1087 on HPV16 (7662-
122) 365 bp sequence. Blue letters indicate the TMG binding site and the highlighted 













0b AAACA-AGCCAAAAATATG-TGCCT 2 7704-7726 reverse (BS) 0.76 1.3 
0c CACAT-ATTTTTGGCTTGT-TTTAA 3 7707-7729 forward 0.76 1.3 
1a TGGCT-TGTTTTAACTAAC-CTAAT 1 7717-7729 reverse  1.32 0.8 
1'a TAACC-TAATTGCATATTT-GGCAT 3 7731-7743 forward 1.32 0.8 
1'a' ATGCC-AAATATGCAATTA-GGTTA 3 7731-7743 reverse (BS) 1.32 0.8 
2 GCCTT-AGTTGTTTAAACC-TTATA 1 7751-7763 reverse (BS) 2.79 0.4 
2'a TTGGC-CTTAGAAGTTTAA-ACCTT 3 7754-7766 forward (BS) 3.9 0.3 
2'a' AAGGT-TTAAACTTCTAAG-GCCAA 3 7754-7766 reverse  3.9 0.3 
3b TTACA-AATGAACAATGTA-TGACT 3 7818-7830 reverse (BS) 5.9 0.2 
3b' AGTCA-TACATTGTTCATT-TGTAA 3 7818-7830 forward 5.9 0.2 
4 GTGCA-GTTTTACAAATGA-ACAAT 1 7826-7839 forward (BS) 2.13 0.5 
5a GCAAC-TTATATAATAATA-CTAAA 1 7888-7890 forward 3.64 0.3 
5a' TTTAG-TATTATTATATAA-GTTGC 1 7888-7890 reverse (BS) 3.64 0.3 
6 TATTA-TTATATAAGTTGC-TTGTA 2 7883-7895 forward (BS) 1.25 0.8 
7a TAGTA-TTATTATATAAGT-TGCTT 0 7886-7998 forward (BS) 1.12 0.9 
7b GCAAC-TTATATAATAATA-CTAAA 1 7888-7890 reverse 1.12 0.9 
7b' TTTAG-TATTATTATATAA-GTTGC 1 7888-7890 forward (BS) 1.12 0.9 
8a TATAT-AATAATACTAAAC-TACAA 1 7894-2 reverse nd nd 
8a' TTGTA-GTTTAGTATTATT-TACAA 1 7894-2 forward (BS) nd nd 
8b ATACA-TGAATTATTGTAG-TTTAG 1 2-14 reverse (BS) nd nd 
9a TACAT-GAATTATTGTAGT-TTAGT 1 1-13 forward (BS) 2.32 0.4 
9b CCCTT-AGTTTTATACATG-AATTA 1 12-25 reverse (BS) 2.32 0.4 
10 ATTCA-TGTATAAAACTAA-GGGCG 1 15-27 reverse 1.6 0.6 
11 ACCGG-TTAGTATAAAAGC-AGACA 2 61-73 forward nd nd 
11b ATGTC-TGCTTTTATACTA-ACCGG 1 62-74 reverse (BS) nd nd 
12a CGGTT-AGTATAAAAGCAG-ACATT  1 63-75 reverse nd nd 
12b TTTGG-TGCATAAAATGTC-TGCTT 1 75-87 reverse (BS) nd nd 
13a AAAGC-AGACATTTTATGC-ACCAA 1 74-86 reverse nd nd 
13b TTTAT-GCACCAAAAGAGA-ACTGC 3 85-97 forward nd nd 
 
. 
The mapping study has shown that the TMG-AHP NV1087 binds with nanomolar 
affinity to the expected binding sites (0 mismatches), as well as to other binding sites (one, 
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two, three mismatches), with comparable Kd values in agreement with previous findings 
for large hairpin polyamides studied by our group.  
To determine how the DNA sequences where the polyamide tail binds, can 
influence the binding affinity the most probable orientations of the polyamide (Table 4.4), 
was taken into consideration. It was found that the presence of G in the tail binding 
sequence increases the Kd values. As an example, for forward binding 1 mismatch, 
compare AC site 7b’ with 4 and 9a. The Kd value increase from 1.12 nM to 2.13 respective 
2.32 at the sites 4 and 9a. The same trend has been observed in the case of reverse 
binding. For reverse binding 1 mismatch comparing AC site 7b, 1a, and 10 with 9b, or for 
the 3 mismatch sites comparing 1’a’ with 2’a’ and 3b, the Kd values have increased 
(Figure 4.6).  
 
Figure 4.6. Binding affinities of NV1087 on HPV16 LCR sequence 
The probabilities of polyamide to bind in forward or reverse orientation had also 
been analyzed. Binding of NV1087 in forward fashion (Figure 4.7 WebLogo 3.4), have 
shown a preference for A and T at the TMG binding site. The polyamide can tolerate 
mismatch nucleotides at almost every position. The middle of the fragment, which contains 




Figure 4.7. DNA binding sequence for forward binding of NV1087 on HPV16 LCR 
fragment. NV1087 in forward fashion have shown preference for A and T at the TMG 
binding site. The middle of the fragment, which contains alternative β/Py is extremely 
flexible allowing for increased mismatch possibilities. 
 
Binding of NV1087 in reverse fashion (Figure 4.8 WebLogo 3.4), have shown a 
preference for A and T at the TMG binding site. Although the polyamide can tolerate 
mismatch nucleotides at almost every position, A and T are preferred through the entire 
binding pattern, the only exception being the imidazole binding site which favors G.  
 
 
Figure 4.8. DNA binding sequence for reverse binding of NV1087 on HPV16 LCR 
fragment.  
NV1087 in reverse fashion have shown preference for A and T at the TMG binding 
site. Although the polyamide can tolerate mismatch nucleotides at almost every position, 
A and T are preferred through the entire binding pattern, only exception being the 





4.4.3 Binding sites of NV1078 on the LCR region of HPV18 (7647-157). 
Comparison of the binding profiles of NV1078 and NV1042 on the LCR region of 
HPV18 (7647-157) 
To better understand the differences between TMG-AHP and the leading antiviral 
compound NV1042 (PA 25) (5, 10) synthesized by our group, the binding profiles of 
NV1078 in the LCR region of HPV18 (7647-157) has been studied. Based on affinity 
cleavage data, the binding sites for NV1078 (MAP ECF3109LCR HPV18) had been 
compared with the binding sites for NV1042 (CHC1139).  
Figure 4.9 illustrates the affinity cleavage sites of NV1078 (A) and NV1042 (B) on 
the same DNA sequence. The box shows the binding sites #7, #8, #8’ and #9 of NV1078 
HPV18 LCR (Map (ECF3109) corresponding to the sites #16, #17, #18, #19 of NV1042 
on the same HPV18 LCR sequence. The underlined region is a G/C reach region where 
the presence of polyamides is weak.  
 
Figure 4.9. Sample electropherogram (bottom strand, Hex dye) illustrating the 
enhanced affinity cleavage sites of NV1078 (A) comparing with NV1042 (B) on the same 
HPV18 LCR DNA sequence. The box shows the binding sites #7, #8, #8’ and #9 (Map 
ECF3109) corresponding to the sites #16, #17, #18, #19 (Map NV1042) in the region that 
includes E1 and E2 proteins binding sites.  
 
As a general overview, an enhancement at four cleavage sites for TMG polyamide 
can be seen. The region in the black box is an A/T reach region (contains about 14% G). 
In this area, a highly enhanced cleavage pattern for site #9 compared with #20 and site 
#7 compared with #16, can be seen. At the position #9 NV1078, most probably binds in a 
1mm forward fashion while NV1042 in 3mm forward fashion. For the 7-16 spot the 0 mm 
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reverse binding has clearly enhanced the cleavage pattern comparing with 2mm, or 3 mm 
binding possibility of NV1042. 
4.5 Discussion 
4.5.1 The binding patterns of polyamides to a certain DNA sequence are not 
completely predictable 
Of the presented data and literature, the hypothesis may be derived that the 
NV1078 polyamide can exhibit the following interactions with dsDNA (Figure 10): 
 
Figure 4.10.  Hydrogen bonds formed by NV1078 polyamide 
The polyamide NV1078 may form hydrogen bonds with the bases in the minor 
groove of ds DNA. From a total of 22 intermolecular hydrogen bonds, 19 are formed 
between the amide hydrogen atoms and the N3 of adenine or O2 of thymine and cytosine 
(hydrogen bond acceptors) that face the minor groove (denoted in red). Furthermore, one 
hydrogen bond between N3 of imidazole and a hypothetical C2-NH-H of guanine (red), 
and two more hydrogen bounds created by the amide hydrogen’s of the polyamide tail, 
according to the bifurcated hydrogen bonds model demonstrated by Dervan, to the N3 of 
adenine and/or O2 of thymine and cytosine (120). According to this model the tail of the 
AHPs sits in the middle of the minor groove and forms hydrogen bonds with 2 DNA strands 
(not marked). An additional third hydrogen bond between TMG and N3 of adenine and/or 
O2 of thymine is possible.  
Positive charges are present at the polyamide C-terminus (Ta) as well as at the N-
terminus (TMG). The positive charge at the N-terminus, unique for this class of 
polyamides, facilitates electrostatic interactions between the tetramethylguanidine and the 
negatively charged phosphodiester backbone of DNA in addition to hydrogen bond 
formation with the base pairs in the minor groove (121). It may be postulated that the 
positive charge at the TMG group has a significant role in the enhanced activity of AHPs. 
The triad Arg-Pro-Arg at the tail end of an 8 ring polyamide had been shown to compete 
successfully for the phosphate backbone and displace the GCN4 protein from the major 
groove (122). In analogy with the guanidinium group of arginine, the TMG may be able to 
disturb the critical binding of E1 helicase in the major groove. 
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Also, the polyamides can establish Van der Waals interactions with the groove 
walls: C2-H of adenine favors van der Waals intermolecular contacts with Py H3 protons. 
Previous docking studies show that the van der Walls stacking interactions in the minor 
groove are more favorable for Py/Py than Py/β configurations (123). Therefore, since 
NV1078 incorporates Py/Py units, favorable van der Waals interactions are expected. The 
NV1087 incorporate five Py/β units, consequently, this molecule is less prone to take 
advantage of van der Walls interactions while bound in the minor groove. 
The exocyclic amino group of G will impede PA fitting in the minor groove (121) 
since deep penetration of the minor groove is required.  The results revealed that although, 
the polyamide tolerates mismatch nucleotides well, the presence of the bulky G base is 
less preferred at the TMG binding sites (Table 4.2 and 4.4). 
Hydrophobic contacts when polyamides bind in the minor groove were not studied 
for NV1078 or NV1087 and can be just anticipated. In the case of 8 ring PAs, the 
hydrophobic contacts  are diminished for Py to β substitution (123). If the same rule applies 
to long polyamides, then for NV1087 (two Py/β pairs) the hydrophobic contacts may be 
diminished. The NV1078 presents two β/β pairs, therefore stronger hydrophobic contacts 
are expected. Since the presence of water weakens electrostatic interactions, it is 
expected that NV1087 have enhanced electrostatic interactions with DNA comparing with 
NV1078. Positive binding entropies are expected since the release of 4 counterions upon 
binding is associated with increased binding entropy. 
4.5.2 TMG-AHP polyamides display similar Kd values as other related 
antiviral polyamides but significantly lower IC50 and IC90 values, therefore 
improved antiviral activity. 
During the experimental work, the thermodynamic parameter, equilibrium 
dissociation constant (Kd), was calculated for a closed system. In these conditions the 
ligand (i.e. TMG-AHP polyamide), and the receptor (i.e. dsDNA) total concentrations were 
constant, only the concentration of the free and bound species changes over time until the 
system reaches equilibrium. The dissociation constant values do not demonstrate a 
severe affinity decrease of the TMG-AHPs at less ideal (two or three mismatches) (Table 
4.2, 4.4) sites in agreement with previous findings for large hairpin polyamides studied by 
our group (11, 86). Moreover, the Kds have shown insignificant variation comparing with 
the Kd values of polyamides less efficient in eliminating the viral load from the same type 
of cells (10, 11) 
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Nonetheless, the IC50 and IC90 values were determined in vivo (open system) 
and showed dramatic improvement in the ability to eliminate the viral DNA from 
keratinocytes comparing with less effective compounds (Table 1.1:  IC50, IC90 for 
different PAs).   
These apparently contradictory results can be explained if we consider that in an 
open system the concentration of the polyamide at the target site can change over time 
due to metabolic processes or other elimination mechanisms (e.g. drug resistance). In 
natural systems, the effect of a ligand depends not only on the selectivity of the ligand and 
its binding properties but also, on the ligand residence time, the amount of time that a 
ligand resides on a given receptor after binding (124), at the certain sites. A longer 
residence time may translate into a persistent biological effect (125). The IC50 and IC90 
values obtained in open biological systems integrate in a better way the factors that 
contribute to the overall response of the cells to the TMG-AHP action(s). 
4.5.3 Viral DNA is capable of adjusting its parameters (intrinsic bending and 
minor groove width) to allow binding of TMG-AH polyamides. By interfering with the 
formation of E1/E2 complex TMG-AHPs block viral DNA synthesis by obstructing the 
replication process at the start. 
The early expressed viral proteins E1 and E2 are essential and sufficient for 
initiation of HPV DNA replication (126, 127). All other factors required for replication of 
episomal DNA are obtained from the host cell. E1 protein contains a DNA- binding domain 
(DBD) and an ATP-ase / helicase domain (128). E1 binds DNA, as a dimer through its 
DBD, along with E2 protein at the viral origin of replication (126) leading to a final double 
hexameric helicase, assembled by E2 protein.  
The ability of the E1DBD to bind DNA as a dimer is required for the assembly of 
E1 as a replication- competent double-hexamer (DH) at the ORI (126). Also, the assembly 
recruits cellular replication factors that will replicate the viral genome. Previous studies 
showed that polyamides that overlap completely (or partially) with the protein binding sites 
are effective at displacing the DNA binding protein by impeding essential amino acid-base 
pair contacts(129). In the cited case, when tandem polyamide binds in the minor-groove 
the intrinsic bending of the DNA will be altered, therefore E2 DBD won’t be able to bind in 
the major groove of the DNA (129). 
From side by side comparison of the AC binding profiles of NV1087 and NV1078 
on the same HPV 16 DNA (Figure 4.10) it was concluded that the TMG-AHP polyamides 
have a preferred binding region where AC cleavage patterns stand out (7880-30). Both 
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polyamides bind in a cluster mode on the ORI of HPV16 that includes the sites of E1 and 
E2 proteins, sites that are critical in the process of the initiation of DNA replication. The 
box in Figure 4.11 shows a cluster of polyamide binding sites. 
 
Figure 4.11.  Mapping studies performed with NV1078 and NV1087 polyamides 
on a 365 bp HPV16 DNA sequence indicate that the polyamides bind with high affinity in 
the region adjacent and overlapping with the E1BS.The preferred binding sites where 
AC cleavage patterns stand out are presented in box. 
 
Since polyamide NV1078 is even more active against HPV18 than HPV16 its 
binding profile on HPV18 LCR (7647-157) sequence was also studied. Although the 
polyamide binds in many different sites, it has a noticeable preference for the sequence 
(7841-43).  Moreover, as a result of the comparison of the binding profiles of a TMG-AHP 
polyamide, NV1078, and the leading antiviral compound PA25 (NV1042), the enhanced 
affinity cleavage region of NV1078 Figure 4.9 convinces us that NV1078 presents 






Throughout our efforts to discover compounds useful in eliminating HPV, during 
the maintenance stage of its life cycle, TMG- AHPs were developed and showed potential 
as possible (antiviral compounds) drugs for the treatment of preexisting and future HPV 
infections. 
The antiviral activity of the compounds was demonstrated by proving the decrease 
of viral DNA levels in human keratinocytes in cells that maintain HPV16, HPV18, and 
HPV31 episomal HPV DNA, without integration of viral DNA (T. Edwards, C. Fischer). 
Two, NV1078 and NV1087, asymmetric TMG polyamides were found to have excellent 
antiviral activity against all three HPV strains HPV16, HPV18, and HPV31. Similar activity 
against different HPV strains is a unique property, (only one more compound the NV1087 
isomer, NV1111, was found to have similar proprieties) most of our compounds distinguish 
between different strains. 
Evidence from biophysical studies supported the primary step of the underlying 
mechanism of action. The large polyamides NV1087 and NV1078, which recognize 13 
base pairs, tolerate well one, two, and three mismatch binding sites. The high tolerance 
of mismatched sequences does not affect the biological activity, suggesting that other 
factors besides sequence specificity, such as the presence of TMG group and possibly 
the residence time, may be crucial for explaining the unique antiviral proprieties of the 
TMG-AHPs. 
Although, the role of tetramethylguanidine groups in the cellular and nuclear 
uptake of TMG-AHPs are not completely understood, our findings are in concordance with 
previous studies that have shown that guanidilated compounds improve the ability of 
compounds for cellular uptake (130, 131).  
Based on the collected data, it may be concluded that the binding of TMG-AHPs 
in a cluster in the region adjacent and overlapping with the E1, E2 binding sites has a 
significant contribution to the overall biological activity.  
The intensive binding in the minor groove of dsDNA (sequence 7880-30 of HPV16 
and sequence 7841-43 of HPV18) of TMG-AHPs structurally alter the dsDNA. The 
required adjustments of the DNA to allow binding may cause the inability of E1/E2 to 
assemble, as a replication competent double-hexamer (DH) at the ORI, obstructing the 
replication process at the start. 
 Moreover, it is rational to predict that the intensive binding in the region mentioned 
above may cause ssDNA exposure or double strand breaks within HPV DNA (6) and the 
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activation of DNA damage response (DDR) pathways (6). Multiple binding sites induce 
DNA nicks which activates ATR. Our findings complement the notion that the PA binding 
to negatively supercoiled HPV episomes activate the DNA damage response (DDR) 
pathways (6). Activation of DDR genes eliminates the viral episomes without having 
substantial effects on cell growth or apoptosis (6).  
The elimination of viral DNA during the maintenance stage it is an effective strategy 
for the development of antiviral compounds. TMG-AHPs have the potential to be useful 





Differential DDR Gene Expression Profile of W12E Cells After  
Treatment with Active Anti-HPV Hairpin Polyamides 
 
5.1 Abstract  
Human papillomaviruses (HPV) infect the basal layer of the epithelium. DNA 
damage response (DDR) machinery can recognize viral DNA and replicating viral genetic 
material as foreign DNA. Low levels of DDR components are expressed in episome 
bearing cells. Once DDR senses DNA damage, it will recruit an elaborate network of 
transducers and effectors to repair the damage or initiate apoptosis. In theory viral 
propagation could be restricted. However, HPV developed ways to take advantage of the 
DDR machinery and coexist with it. Moreover, HPV uses DDR elements for its replication.  
It had been shown that in addition to induction of DDR genes by HPV, anti-HPV 
polyamide treatment of episome-bearing cells also causes the alteration of some DDR 
gene expression levels (6, 117). Gene products that act as both enhancers and repressors 
of anti-HPV activity of polyamide PA25 were identified (6). The goal of the present study 
is to compare (and find the common features of) the effects of the polyamides NV1078 
and NV1042 on genome regulation, using NV1011 as a control like in the previous study 
(6).  
The polyamides’ effects on DDR gene expression were analyzed after treatment 
of W12E cells with the polyamides mentioned above. W12E cells are undifferentiated 
cells, harboring 100-500 viral episomes per cell. Therefore, they were used as model for 
gene expression studies of cells mimicking the maintenance phase of the HPV lifecycle. 
Total RNA was extracted and converted to cDNA.  To measure the transcript abundance, 
seven DDR genes and five reference (housekeeping) genes were analyzed in parallel.  
The goal of this project was to have an initial feedback before completing analysis 
of RNASeq data on polyamide effects. QPCR studies monitored expression of the seven 
DDR genes (Table 5). These genes are the Transducers (Ataxia-telangiectasia mutated 
kinase, ATM and Ataxia telangiectasia and Rad3-related protein, ATR (8)) and first line 
effectors (CHEK1, CHEK2) in the homologous recombination (HR) pathway. Also, RAD1, 
RAD9A and TP53 were included in the study (Table 5.5 and Chapter 1). 
The gene expression analysis is expected to lead to the identification of genes 
relevant to the polyamide mechanism of action and provide insight into the complex 
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regulatory DDR networks. Additional QPCR work will be done to follow up and test the 
RNASeq results. 
5.2 Introduction. DDR response in cells infected with HPV16 
The virus HPV has a complex relationship with the infected host cells. In its intricate 
association with the DDR, the virus has to accomplish two important tasks to replicate in 
the host cell. First, the virus has to evade the DDR, which senses foreign DNA and DNA-
bound viral proteins as a threat to genomic integrity. Moreover, the virus has to use 
elements of the DDR to complete its own deficient transcriptional machinery. 
Suppression of DNA damage response is achieved by viral proteins E6 and E7, 
which act as direct or indirect antagonists of different DDR components. E6 and E7 interact 
with DDR components in addition to their other functions. The principal function of E6 and 
E7 proteins is to maintain the keratinocytes in a proliferative state. This function is 
achieved in part when E7 inactivates Retinoblastoma protein (pRB) and E6 targets the 
protein p53 for proteasomal degradation, therefore preventing the cell from undergoing 
apoptosis. The two oncogenic viral proteins E6 and E7 work cooperatively to avoid 
downstream signaling, therefore undermining the DDR response in undifferentiated and 
differentiated host cells (9, 48, 113, 114).  
Among numerous functions of viral oncogene E7 (see Introduction, Chapter 1 (1)) 
is its ability to abrogate the ATM-ATR pathway-induced checkpoints. E7 causes the 
degradation on claspin, a key regulator of ATR-CHK1 pathway, therefore promoting 
mitotic entry in the presence of foreign DNA (1).  
Similarly to E7, E6 creates interactions with a multitude of cellular proteins. Among 
those, the relation with p53 is important from a DDR point of view, since activation of the 
ATM and ATR signaling cascades leads to phosphorylation of the p53 tumor protein 
(Figure 1). The oncoprotein E6 antagonizes the function of p53, forming an E6-E6 
associated protein (E6AP)-p53 and targeting p53 for proteasomal degradation (132). In 
this way, E6 eliminates the p53-dependent apoptosis (1). Furthermore, E6 interferes with 
p53 at a genomic level. The interaction of E6 with histone acetyltransferases p300, CREB 
binding protein, and ADA3 prevents p53 acetylation, and through this, inhibits the 
transcription of p53 responsive genes (1). 
Manipulation of DDR promotes the viral lifecycle. HPV utilizes both the ATM (9, 
19) and ATR (5, 133) pathway for replication and vegetative amplification. The ATM 
pathway components have been shown to be critical regulators of HPV in the amplification 
phase of differentiated keratinocytes. Nevertheless, the pathway is activated in 
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undifferentiated cells as well (9).  Multiple viral proteins can activate ATM pathway and 
work independently or cooperatively to promote viral replication as shown in Table5.1.  
Table 5.1. Viral proteins that activate the DDR pathways to replicate the viral genome by taking 






Effect on cells 




replication centers inducer 
  
E7 
G2/M arrest; CHK1, CHK2 
activation; STAT-5 activation 
ATR E1 CHK1 activation 
 
Viral helicase E1 is the major activator of ATM in undifferentiated cells, expressing 
a complete viral (HPV11, 16, 18, 31) genome (34). Nuclear accumulation of E1, leading 
to nonspecific DNA unwinding, may result in the induction of undesired DNA breaks in the 
host genome (133), and consequently, induction of ATM pathways and arrests in the S 
phase, allowing viral replication. E1 helicase activity is attenuated by complex formation 
with E2 or by nuclear export (34). Both events, complex formation and nuclear export, are 
paramount, as they will keep low levels of E1 in undifferentiated cells, desirable to avoid 
genomic instability generated by ds DNA breaks which could favor integration of the viral 
genome (34).  
The E2 viral protein ameliorates E1 effects but also activates the ATM pathway 
following an entirely different mechanism. E2 binds to BRD4, which tethers the episomes 
(HPV 16, 18) to the host chromatin (35)  to ensure replication in the initial amplification 
phase and the maintenance phase. This tethering mechanism ensures that the low copy 
of the viral genome is retained in the nucleus, and it is partitioned to daughter cells. BRD4 
interacts with chromatin and has a significant role in the formation of the viral replication 
centers(36, 41). Therefore, E2/BRD4 complex is an intermediate component that attracts 
cellular proteins to viral replication centers to initiate the replication of viral DNA. ATM 
homologous recombination elements pATM, pH2AX, and pNBS1 are colocalized with 
BRD4/E2 proteins in the replication centers (43). Replication centers were spotted and 
detected by confocal imaging in differentiated and undifferentiated (HFK-HPV16E1/E2) 
cells as well (43).  
Viral proteins, in particular oncoproteins E6 and E7, which drive an aberrant 
proliferation of the cells, provoke a DDR response used by HPV for viral replication. The 
viral E7 protein has been shown to activate the ATM pathway (1) and its downstream 
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effector CHK2 in differentiated as well as undifferentiated cells harboring the HPV31 virus 
(9). Phosphorylation of ATM and its downstream effector CHK2, as well as CHK1, was 
also observed in cells harboring HPV18 (134). 
Activation of the ATM response in cells induces a G2/M arrest that provides an 
environment favorable to productive viral replication (9). It is important to notice that NBS1 
(Nijmegen breakage syndrome 1, also known as nibrin), part of the Mre11–Rad50–Nbs1 
MRN sensor complex which promotes monomerization and autophosphorylation of the 
ATM kinase, is only activated in differentiated cells (1). It was also shown that the 
formation of viral replication centers in differentiating cells is dependent upon ATM activity, 
for pATM, pCHK2, pNBS1, and γH2AX are present in the amplification centers (9).  
In addition, E7 forms complexes with phosphorylated ATM proteins (113), but not 
the unphosphorylated form of ATM (9). This interaction may allow ATM to recognize novel 
substrates (9). In the same paper, it was demonstrated that although the ATM pathway is 
activated in undifferentiated cells, it is not essential for stable maintenance of viral genome 
(9). ATM activation is necessary for viral genome amplification in differentiating cells (9).  
E7 also activates the cytosolic transcription factor STAT-5 (15). The 
phosphorylated STAT-5 induces increased levels of PPARγ (a nuclear transcriptional 
factor) in HPV31 positive cells, which (possibly with the help of additional intermediary 
proteins) activates the ATM DNA damage pathway (8) leading to genome amplification 
(15).  
Hitherto, it is unclear how ATM factors specifically contribute to replication. It was 
hypothesized that the primary function of ATM factors is to help resolve concatemers of 
viral DNA, or that viral replication is mediated by DNA repair polymerases and ligases 
(15).  
Complementing ATM factors, HPV also utilizes the ATR pathway for replication 
(133) (5, 6). Using U2OS cells transfected with the E1 protein expression constructs, 
HPV16 and HPV18 were shown to activate the phosphorylation of ATR and CHK1 in 
undifferentiated and differentiated cells, and members of the ATR pathway localized to 
HPV replication centers (133).  
Inhibition of ATR pathway components reduces the number of HPV episomes that 
are stably maintained in W12 keratinocyte cell lines, suggesting a role of the ATR pathway 
in HPV16 replication in undifferentiated cells (5, 6). 
Moreover, the previous DDR gene study (6) showed that 11 genes were employed 
by the virus to maintain the episome levels in cells in natural conditions during the 
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maintenance phase (6). Among those eleven genes that augment the HPV16 episome 
levels in W12E cells, three are members of the DDR pathways, ATM, RTEL1 (an HR 
suppressor), and RUVBL2 (a helicase essential for DBS repair). 
The ATM transducer and CHEK2 effector play an important stabilizing role for the 
HPV episome that does not require kinase activity (5, 6); the ATR transducer and CHEK1 
effector stabilize the  HPV, lessening the replication fork effects generated by E1 and host 
replication factors (which is thought to be intrinsically unstable (117). 
Large PA’s alter the DDR response initiated by HPV episomes 
As shown, the HPV episomal DNA by itself mediates a DDR response in cells 
infected by the virus not just in the amplification phase, but also in the maintenance phase. 
The extent of DDR involvement is directly proportional to the HPV episome numbers 
present in cells. 
Previous studies have shown that the large PA25 induces a DDR response in cells 
infected with the HPV virus (5, 6, 117). The significant viral loss registered when infected 
cells were treated with an active polyamide is a consequence of the degradation of the 
viral episome, not just the inhibition of viral DNA replication (117). No such response was 
observed when cells that contained already integrated HPV were treated with the same 
polyamide (117).  Also, when treated with PA 25 the viral episome from infected cells was 
cleared without integration in the host chromosomes (6, 117). Simultaneously, DDR genes 
were upregulated or downregulated as a result of PA25 binding in the minor groove of 
episomal DNA (6, 117).  
The activation of DDR pathways and the use of their elements for viral 
maintenance was evidenced in W12E cells using siRNA-mediated knockdown of the DDR 
genes. Knockdown or inhibition of the transducer genes ATM and ATR and other proteins 
in the DDR pathway lead to the decrease of episome numbers. A drastic 40%–50% 
reduction in the HPV16 copy number in W12 cells was registered (5, 6, 8). 
The degradation of the viral episome was supported by the Aphidicolin action on 
viral episomes. Aphidicolin, a selective α-polymerase inhibitor with antimitotic proprieties, 
is known to activate a DDR (ATR) response and cause significant episome loss when 
used for the treatment of cells infected with viral episomes (5). Meanwhile, no significant 
changes were registered when Aphidicolin was used on infected cells already treated with 
polyamides. The episomes already degraded by polyamides are uninvolved in the 
response to Aphidicolin treatment.  The goal of the present study is to find the similarities 
72 
 
and differences in the way of action of the PA’s presented in Table 5.2 by the RT-QPCR 
method.  
Table 2. Polyamides used in RT-qPCR studies. The IC50 and IC90 values measured for W12E 
cells were determined by T. G. Edwards in the Fisher lab, unpublished data. 
PA PA sequence IC50 [µM] IC90 [µM] 
NV1011 (PA11) ImPPIm-γ-PPPP-β-Dp NOT ACTIVE NOT ACTIVE 
NV1042 (PA25) ImPP-β-PPIm-β-PP-γ-PPβPPPβPPP-β-Ta 0.036 0.351 
NV1078 (TMG-AHP) TMG-PβPPIm-β-PP-γ-PP-β-PPP-β-PPP-β-Ta 0.046 0.307 
 
5.3 Materials and Methods 
5.3.1 Cell Culture; W12E Keratinocyte Cells (clone #20850)  
The Keratinocyte cell line (W12E clone #20850) containing HPV16 genomes as 
episomes (10, 135, 136) was maintained in monolayers in E-media (3 parts DMEM with 
high glucose, and one part F12 media) in the presence of mitomycin C treated 3T3 
fibroblast feeder cells. 
The 3T3 cell line is a fibroblast cell culture (ATCC NIH/3T3) established from the 
disaggregated tissue of an embryonic albino Swiss mouse. The 3T3 feeder cells used in 
this experiment were received from the lab of Paul Lambert on 25 Dec 2009, and were 
stored in liquid nitrogen (J23T3 GH2012). In culture, 3T3 cells can form confluent 
monolayers with contact inhibited cell motility. The 3T3 cells could grow indefinitely and 
do not instigate tumor growth. The 3T3 fibroblasts (Figure 1) are used as feeder cells for 
keratinocyte cells (W12E) because they secrete growth factors favorable for keratinocytes. 
Thus, they enhance the growth of human keratinocytes and shorten the cultivation time of 
said keratinocytes. The 3T3 fibroblasts have been maintained in a monolayer culture to 
80% confluence in growth media (DMEMF10 - Dulbecco's Modified Eagle's Medium 
supplemented with 10% BCS and 1% pen-strep). The cells were grown in a 37 C̊, 5% 
CO2, humidified incubator and passaged to 1:10 every three days based on  previously 
published protocols (137) (Cell culture, 3T3 Protocol: ECF3133). The 3T3 cells were 
incubated with mitomycin for 2 hours at 37°C in a 5% CO2   humidifier incubator. 
Mitomycin C from Streptomyces caespitosus, which inhibits the proliferation of 3T3 
cells, was added to the 3T3 cells before being used as feeders for keratinocytes, to a final 
concentration of 8 µg/mL (200 µL 50X mitomycin C per 10 mL E-medium (138). Mitomycin 
C (Figure 1) treatment was utilized to stop the division of the 3T3 cells. Mitomycin C reacts 
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covalently with DNA, crosslinking complementary strands and inhibiting DNA replication 
(137).  
 
Figure 5.1.  Mitomycin C structure 
The W12 cell line which is representative of a premalignant HPV16 induced tumor 
was derived from a low-grade cervical lesion and retains the HPV16 genome as an 
episome (139).  W12E cells contains a frameshift mutation in the E1 gene (140) with the 
accession number on GenBank as AF125673.The W12E keratinocyte cells (Figure 1.B) 
harbor extrachromosomal HPV16 genomes with HPV16 copy numbers ranging from 300 
to 500 copies per cell (5, 10, 135). In the basal layer, the initial stage of infection, the 
episome number is considered to have little copy number variation, and it is considered 
stable. 
The W12E clone #20850 cells, maintained at early passage (from P #13 to P #17) 
have been cultured in monolayers on top of a mitomycin treated 3T3 feeder layer. Clone 
20863 W12E cells are known to be differentiated keratinocytes (141) 
High passage number was avoided since W12 cells grown in long-term cultures 
have the ability to differentiate (142).  The cells were maintained at 37 ̊C in a humidifier 
incubator with 5% CO2 in a medium consisting of E-media (3 parts DMEM w/ high glucose, 
pyruvate and 1 part F12 media) supplemented with 0.4 μg/ml Hydrocortisone, 0.1 nM or 
10 ng/ml Cholera toxin, 5 μg/ml Insulin, 24 μg/ml Adenine, 10 ng/ml Epidermal Growth 
Factor, 5 µg/ml Transferrin, 20 pM 3,3,5-Triiodo-thyronine (T3), 1% 
Penicillin/Streptomycin, and 5% Fetal Bovine Serum (5). The media components were 
filtered using syringe filters (Millex-GP 0.22 µm) and aliquoted. The prepared E-Complete 
and E-Incomplete (contains no EGF) cell media were sterilized using Nalgene 0.2 PES 
filters. The E-Incomplete media was used for culturing keratinocyte and 3T3 feeder cells 
the first day after passaging. The W12E cells have been passaged at 70% confluence 
using a split ratio of 1:10 (5) (Epithelial cell culture protocol: ECF3134). 
The W12E (1x105) cells were seeded on the top of 1x105 mitomycin treated J23T3 
fibroblast cells in 6 well plates (Sigma-Aldrich, CLS3516-50EA). The working volume of a 
six-well plate is 1.9-2.9 ml, the growth area is 9.5 cm2, and the expected cell yield varies 
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between 9.5 x 105 to 106 cells. The cells were plated at a density of 1x105 cells/ml. Table 
5.3 includes the passage numbers of the cells used for obtaining the biological replicates. 
Table 5.3. The W12E and the 3T3 passage numbers used for obtaining 5 series of 
biological replicates. Also, the RNA extraction dates and the notebook page numbers 
are included. 
 Series 1 Series 2 Series 3 Series 4 Series 5 
W12E cells P13 P14 P15 P16* P17 
J23T3 cells 
Set I/Set II 
P22/P18 P23/P19 P24/P20 P25/P21 P26/P22 
Total RNA 
extraction Set 

























Set I polyamides refers to polyamides NV1078, NV1087(6102A), NV1042 
(KJK6006) (6) NV1028 (GDH1130) NV1111(KA2092) . Set II polyamides refer to NV1011 
(KJK1083D 88%), NV1113(KJK6169), and NV1115 (KJK6170) 
*According to Garner-Hamrick (135) P16 W12E will have about 1273 HPV copies 
per cell, while according to Edwards (5) P16 will have 300-500 copies per cell.  
 
Figure 5.2. Confocal image of live W12E cells incubated with DRAQ5 for 10 min.  λ= 
639 nm, 40X, (ECF 1130.6). The W12E are polygonal in shape with relatively regular 
dimensions and grow attached to a substrate in discrete patches. The Keratinocyte W12E 
cells form clusters among 3T3 cells. The image was acquired with a Zeiss LSM 700 laser 
scanning confocal microscope (LSCM). 
The cells were plated in 6 well plates at a seeding density of 1x105 J23T3 cells and 
1x105 W12E cells in 2 ml E-media. The number of cells was determined using a Nexcelom 
Bioscience Cellometer Auto T4 instrument (cell counting chambers plates SD100). 
311.86μm x 311.86μm 
311.86μm x 311.86μm 
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The W12E cells are identified as biohazardous agents as representatives of Risk 
Group 2 (RG2). The detailed workflow of the cell culture experiments was submitted for 
approval to the Institutional Biosafety Committee. The experimental work was done in 
compliance with standards and regulations according to NIH guidance biosafety level 2 
(BL2) (143). 
5.3.2 Treatment of the cells with active polyamides 
The W12E cells have been treated with 7 active polyamides, an inactive polyamide as 
a negative control (Table 5.2), and 0.1% DMSO vehicle as control. The cells were 
incubated with polyamides on day two for 24 hours. It was assumed that the selected PA’s 
follow the same pathway during uptake within the cells (see introduction).  
The IC50 and IC90 values (Chapter 1) which show the effectiveness of PAs clearing the 
HPV episomes from infected cells were used as guidance to decide the polyamide 
concentration. The cells had been treated with 0.1 μM PA for 24 h.  
Lyophilized aliquots of PAs were resuspended in 20 µL sterile DMSO (100µM). 2 µL of 
polyamides were added to 1998 µL of E Complete Media on the second day of culturing 
the cells. The cells were incubated for another day (24 hours precisely). In this way, the 
final polyamide concentration in the media was 0.1 µM in 0.1% DMSO. The lyophilization 
solvent was composed of 50% (water + 0.1% TFA), and 50% (Acetonitrile + 0.1%TFA). 
5.3.3 Extraction of total RNA  
RNA extraction optimization. Before collecting the RNA used for subsequent 
experiments, experimental trials were used to decide the proper incubation volume and 
the protocol steps for harvesting the cells and extracting the RNA. It was found that 300xg 
centrifugation speed for 5 minutes works well when using either an Eppendorf 5424R, a 
FA-45-24-11, an Eppendorf mini spin, a F-45-12-11, or a Sorval ST16R centrifuge for cell 
pellet collection. When using QIAshredder and RNeasy spin columns, 12,500g 
centrifugation speed was used. It was found that 2 ml of cell suspension containing 2.6 x 
105 cells yielded an RNA concentration of 0.9 µg/ml. This concentration was found proper 
for downstream experiments. Therefore, the cells were plated in 6 well plates at seeding 
density of 1x105 J23T3 cells and 1x105 W12E cells in 2 ml E-media. The RNA 
concentration was measured using Epoch Microplate BioTek spectrophotometer 
equipped with Gen 5 software. Based on absorbance values, the concentration of RNA 
was calculated based on the equation 
CRNA = 44ng/µL X A260 X dilution factor 
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RNeasy procedure. The total RNA (viral and genomic) was extracted following 
the RNeasy Plus Mini Kit, Qiagen 74134, protocol (ECF4008).  Through the RNeasy 
method, all RNA molecules longer than 200 nucleotides were purified. The process 
provides enrichment for messenger RNA (mRNA) since most RNAs shorter than 200 
nucleotides, such as ribosomal RNA (rRNA, makes up ribosomes along with other 
proteins), and transfer RNA (carries amino acids to mRNA to form polypeptides) are 
excluded from the purified pool. The goal of the purification process was to capture the 
mRNA which carries the genetic information of DNA from the nucleus to the cytoplasm for 
protein synthesis.  
Cells grown in a monolayer seeded at a density of 1x105 J23T3 cells and 1x105 
W12E cells in 2 ml E-media were trypsinized and resuspended in medium containing fetal 
bovine serum to inactivate the trypsin. The cells were collected as a cell pellet before lysis. 
To improve the RNA yield, complete removal of the cell-culture medium was necessary. 
The culture media can inhibit lysis and also dilute the lysate, disturbing the binding of RNA 
to the RNeasy membrane.  
Cells were disrupted by adding Buffer RLT, a guanidine-thiocyanate–containing 
buffer. Guanidine thiocyanate (GATC) is an extremely potent chaotropic agent which 
quickly denatures macromolecules and inactivates nucleases. GATC disrupts any 
hydrophilic bonds, therefore lysing the cell membrane, linearizing nucleic acids, and at the 
same time completely destabilizing RNAses. In the lysis buffer, RNA is perfectly 
protected. The Qiagen RLT buffer composition is confidential, but usually lysis buffers 
contain guanidine thiocyanate (5M-10M) which is dissolved in Tris-HCl (0.1 M) + 0.5M 
EDTA + Tween-20 or Triton X-100.  
To ensure total inactivation of RNases, beta-mercaptoethanol (β-ME), 1 µL to the 
1 ml buffer, was also added to the RTL buffer. An additional step for homogenization of 
the lysate with QIAshredder, Qiagen 79654 spin columns was introduced. After 
homogenization, the lysates were transferred to a gDNA eliminator spin column and 
centrifuged at high speed (12,500g).  
To provide appropriate binding conditions to the column membrane, ethanol was 
added to the flow-through, and the samples were applied to an RNeasy Mini spin column. 
The RNA binds to the positively charged columns’ (silica, porous glass) membrane in the 
presence of the high salt concentration. Contaminants were efficiently washed away using 
Buffer RW1 (contains guanidine salt, which removes carbohydrates) and Buffer RPE 
(wash buffer containing ethanol). 
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The total RNA bonded to the column membrane was eluted with 60 µL of RNase-
free water. The RNA samples are stored at -80 °C as aliquots of: 20 µL (for further 
RNASeq experiments), 20 µL (for further QPCR experiments), 17 µL (for DDR-QPCR), 
and 3 µL (for quality and quantity determination, RIN). The first set of samples was used 
for TruSeq library preparation (Chapter 6), the second set was stored for RNASeq 
validation experiments (after bioinformatics will communicate us the whole spectrum of 
genes that were altered), and the third was used to analyze the polyamide’s effects on 
DDR gene expressions for immediate feedback.  
5.3.3.1 The quality of total RNA  
Assessing the quality of starting material for downstream experiments is very 
important since high quality RNA is needed to correctly assign the mRNA expression 
levels. The quality and quantity of the total RNA was determined using the BioAnalyzer 
Agilent 2100 instrument in compliance with Agilent RNA 6000 NanoKit protocol (5067-
1511).  
The RNA integrity of total RNA samples purified from W12E cells bearing HPV16 
episomes, was tested using 1 µL of the total RNA.  In every well of the chip of 
interconnected microchannels, 1 µL of total RNA was added to a support of 5 µL of gel-
dye. The nucleotide fragments have been separated, as they were driven through 
electrophoretically and the results were registered as an electrophoretic trace. 
The electrophoretic trace (electropherogram) provided the RNA integrity number 
(RIN), the total RNA concentration of the samples, and the ribosomal ratios. RNA integrity 
number (RIN) is a software tool that estimates the integrity of the RNA samples and 
assigns an integrity number to eukaryote tRNA samples when the concentrations of the 
samples are > 25 ng/µL (Agilent Technologies, Palo Alto, CA, USA). To estimate the RIN, 
the entire electrophoretic trace is considered, not just the ribosomal bands ratio. The 
ribosomal ratios are frequently used to determine the integrity of the RNA samples. If 
28S/18S > 2 or higher, the 28S/18S ratio is an indication that the purified RNA is intact 
and hasn't degraded. 
The electropherograms obtained after the extraction of the RNA which allow for visual 
inspection of RNA integrity are provided in the supplementary material. The RIN scores 
and the concentration of the samples are provided in Table 5.4. 
5.3.4 Reverse Transcription of RNA 
After treatment with polyamides (0.1 µM, 24 h in cell growth media), the W12E total 
RNA was extracted according to the RNeasy procedure and converted to complementary 
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DNA (cDNA). cDNA was synthesized from 1 µg of DNA-free total RNA in a 20 µL reaction 
volume using a Maxima First Strand cDNA Synthesis Kit for Reverse Transcription 
qualitative PCR (RT-qPCR) (K1641 Thermo Fischer Scientific). The kit employs the 
Maxima Reverse Transcriptase Enzyme, an advanced enzyme derived by in vitro 
evolution of M-MuLV RT, and oligo (dT)18 and random hexamer primers to prime synthesis 
of first strand cDNA. The oligo (dT)18 is specific for mRNA and initiate reverse transcription 
at the 3’ end of the transcript. Random primers are used only in two-step qRT-PCR 
reactions. The negative control, reverse transcriptase minus (RT-), was performed to 
evaluate for genomic DNA contamination of the RNA sample. For every biological 
replicate, 1µg of total RNA was used for reverse transcription.  
Table 5.4.  RIN, volumes and concentrations of total RNA samples used for reverse 
transcription corresponding to 1 µg sample. 
PA-Replicate RIN*  Total RNA (ng/µL) tRNA µg (17μL)  ͣ  tRNA(μL) 
NV1078-1 10 314 5.3 3.2 
NV1087-1 10 644 10.9 1.6 
NV1042-1 10 352 6.0 2.8 
NV1028-1 10 192 3.3 5.2 
NV1111-1 10 330 5.6 3.0 
 0.1%DMSO-1 10 275 4.7 3.6 
NV1078-2 10 369 6.3 2.7 
NV1087-2 10 690 11.7 1.4 
NV1042-2 10 521 8.9 1.9 
NV1028-2 10 472 8.0 2.1 
NV1111-2 10 335 5.7 3.0 
 0.1%DMSO-2 10 542 9.2 1.8 
NV1078-3 10 127 2.2 7.9 
NV1087-3 10 118 2.0 8.5 
NV1042-3 10 99 1.7 10.1 
NV1028-3 10 92 1.6 10.9 
NV1111-3 10 93 1.6 10.8 
 0.1%DMSO-3 10 122 2.1 8.2 
NV1078-4 10 239 4.1 4.2 
NV1087-4 10 307 5.2 3.3 
NV1042-4 10 252 4.3 4.0 
NV1028-4 10 278 4.7 3.6 
NV1111-4 10 277 4.7 3.6 
0.1%DMSO-4 10 301 5.1 3.3 
NV1078-5 10 330 5.6 3.0 
NV1087-5 10 308 5.2 3.2 
NV1042-5 10 335 5.7 3.0 
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PA-Replicate RIN*  Total RNA (ng/µL) tRNA µg (17μL) ͣ  tRNA(μL) 
NV1028-5 10 155 2.6 6.5 
NV1111-5 10 394 6.7 2.5 
 0.1%DMSO-5 10 278 4.7 3.6 
 NV1011-1 10 134 2.3 7.5 
NV1113-1 9.9 126 2.1 7.9 
NV1115-1 10 219 3.7 4.6 
 NV1011-2 10 232 3.9 4.3 
NV1113-2 10 110 1.9 9.1 
NV1115-2 10 166 2.8 6.0 
 NV1011-3 10 87 1.5 11.5 
NV1113-3 10 82 1.4 12.2 
NV1115-3 10 51 0.9 19.6 
NV1011-4 10 179 3.0 5.6 
NV1113-4 10 112 1.9 8.9 
NV1115-4 10 18 0.3 55.6 
NV1011-5 10 179 3.0 5.6 
NV1113-5 10 170 2.9 5.9 
NV1115-5 10 136 2.3 7.4 
*Bioanalyzer data from ECF4030 
ͣTotal RNA aliquot for DDR qPCR experiments 
 
The reaction components were incubated for 10 min at 25 °C followed by 15 min 
at 50 °C. Reverse transcription of RNA extracted from W12E cells after treatment with 
polyamides was terminated at 85 °C (5 min) in agreement with the K1641 protocol. cDNA 
was stored at -20 °C for a week or -80 °C for further experiments. 
5.3.5 Real Time - Quantitative Polymerase Chain Reaction (RT-qPCR). 
Relative quantification method. Normalization against reference genes  
 To assess the gene-specific transcription levels, the first strand cDNA was primed 
with specific primers (DNA Repair II Pathway PCR array, HDRL-II, RealTimePrimer) which 
hybridized to the reference genes or the chosen target DDR genes. The control genes, 
further named reference gene primers, were supplied along with the Human DNA Repair 
Primer Library II (RealTimePrimer).  
Real-time quantitative PCR is a fluorescent-based method which permits the 
detection of small amounts of DNA in a large variety of samples. Single-stranded cDNA 
was transformed into dsDNA in the presence of Maxima SYBR Green ROX qPCR Master 
Mix (Fermentas, K0221). The initial amplicon amount was measured with a BioRad CFX96 
Real-Time System. The quantitative PCR (q-PCR) reaction was performed using a two-
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step cycling protocol, following cycling conditions: 1X 95 °C for 10 min (initial activation of 
enzyme Maxima Hot) followed by 40 cycles of 95 °C for 10 sec (denaturation), 58 °C for 
45 sec (annealing and extension) (6). Hard shell PCR plates (HSP9601 Bio-Rad) were 
sealed with PCR Microseal “B” film (MSB1001).  
The master mix used included Maxima Hot Start Taq DNA Polymerase and 
dNTPs. Maxima Hot Start Taq DNA Polymerase is a Taq DNA polymerase which is 
inactive at room temperature. The qPCR buffer contains KCl and (NH4)2SO4 to provide 
high specificity of primer annealing. 
The SYBR Green I is an intercalating dye that allows DNA detection and analysis 
without using sequence-specific probes. SYBR Green I is a fluorescent intercalating dye 
that emits a fluorescent signal when it binds to the double stranded DNA. The fluorescent 
signal is proportional to the dsDNA concentration (Figure 3). The excitation maxima of 
SYBR Green I is 494 nm and emission maxima is 521 nm.  SYBR Green I is compatible 
with the use of BioRad CFX96 Real-Time System.  
 
            
A                  B 
Figure 5.3. (A) SYBR Green I structure, (B) SYBER Green I upon binding to dsDNA 
emits fluorescence very brightly, (B) Signal intensities correlate with DNA amplified, thus, the 
initial sample input amount. 
For normalization of the SYBR Green I, ROX is used as a reference dye (Figure 
5.4). It allows for correction due to pipetting imprecisions and fluorescence variations. 
ROX does not participate in a PCR reaction. The excitation and emission maxima are 580 
nm and 621 nm. 
 
Figure 5.4. ROX chemical formula 
After purification of the total RNA from cells, reverse transcription of RNA, real-
time PCR reactions were performed for five biological replicates of four cDNA samples. 
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The samples were: (1) the control sample represented by cells treated with vehicle, 0.1 % 
DMSO, (2) cells treated with 0.1 µM NV1078 polyamide for 24 hours, (3) cells treated with 
0.1 µM NV1042 polyamide for 24 hours, and (4) cells treated with 0.1 µM NV1011 for 24 
hours. The transcription level was measured for 7 DDR target genes, ATM, ATR, RAD1, 
RAD9, CHEK1, CHEK2, and TP53 (Table 5.5), and for 5 reference genes: ACTB, PGK1, 
GAPD, PPIA, and RPL13A (Table 5.6).  
The transcription levels of one set of biological replicates were analyzed in the 
same time in the same 96-well plate (Bio-Rad) to minimize run-to-run differences, and the 
same threshold setting was used for the determination of the quantification cycle values 
(Cq). The raw quantification cycle values for the biological replicates are presented in 
Tables 7, 9, 11, and 13. 
Table 5.5. Target DDR genes used in the study 
 
Human Gene Gene Symbol  Activity/Repair Citation 
Ataxia Telangiectasia 
Mutated 
 ATM  DSB Repair (5, 6, 9) (34)  
Ataxia Telangiectasia and 
Rad3 Related 
ATR  SSB Repair (5, 6, 9)  
Rad1 Homolog 
 





RAD9A  9-1-1 complex member (6) 
Chk1 Checkpoint Homolog 
 
CHEK1  DDR ATR checkpoint 
effector 
(5, 6) 
Chk2 Checkpoint Homolog 
 
CHEK2  DDR ATM checkpoint 
effector 
(5, 6) 




The reference genes (Table 5.6) should be stably expressed. The expression level 




























Phosphoglycerate kinase 1 
 
PGK1 +++ Phosphate group transfer in 
glycolytic pathway 
Peptidyl prolyl isomerase A 
 
PPIA +++ Cis-trans isomerization of 
proline imidic peptide 
bonds 
Ribosomal protein L13A 
 
RPL13A +++ Structural component of the 
large ribosomal subunit 
Glyceraldehyde-3-phosphate 
dehydrogenase 




The specific primer set sequences for target genes (Table 5) as well as reference 
genes (Table 6) are not disclosed by the vendor (RealTimePrimer). A possible primer 
sequence can be found on the RT Primer Data Base website (RTPimer) which is a 
collection of submitted primer pairs and assays used in RT-qPCR experiments.  
The expression of target genes normalized to 5 reference genes and relative to a 
calibrator (untreated cells) was calculated based on the Livak (ΔΔCq) method (144) 
according to Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines (145). 
The Livak method requires that the target and reference gene amplify at 
efficiencies near 100% and have efficiencies within 5% of each other.  Three steps are 
required for calculations (1) normalize Cq (target gene) to Cq (reference gene) for control 
samples and test samples; (2) normalize ΔCq of the test sample to ΔCq of the calibrator 
(control); (3) Calculate expression ratio, or fold difference. 
1. Normalize Cq of the target gene to Cq of the reference gene 
ΔCq(calibrator) = ΔCq(control) = Cq (target, calibrator) - Cq (reference, calibrator) 
ΔCq(calibrator) = ΔCq(control) = Cq (target, calibrator) - average Cq (ref., calibrator) 
Cells treated with vehicle 0.1% DMSO are the control cells 
ΔCq(test) = Cq (target, PA treated) - Cq (reference, PA treated) = ΔCq(PA) 
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ΔCq(test) = Cq (target, PA treated) – average Cq (reference, PA treated) = ΔCq(PA) 
2. Normalize ΔCq of test sample to ΔCq of calibrator 
ΔΔCq = ΔCq(calibrator) - ΔCq (test) 
3. Calculate the fold difference in expression 
Normalized Expression Ratio = RQ=2ΔΔCt 
The RQ values obtained in this way represent a change in the expression of the gene 
of interest between the test and the calibrator conditions normalized for any differences in 
loading between the reference and test samples. 
5.4 Results and Discussion.  Effects of polyamides on 7 DDR gene 
expression 
The goal of this project was to have an initial feedback (before the analysis of 
RNASeq data) on polyamide effects regarding gene expression. RT-QPCR studies 
monitored expression of the seven DDR genes (Table 5.5) at the mRNA level. 
Herein, the effects of three polyamides on 7 DDR gene expression compared with 
the expression of the genes in the control cells is presented. Description of procedure in 
a nutshell: 
W12E cells were seeded in six-well plates (1X105 cells per well) over (1X105 cells 
per well) mitomycin treated 3T3 cells and treated with 0.1 µM PA for 24 h. The total RNA 
was extracted and purified using RNeasy Plus Mini Kit along with QIAshredder 
homogenizer columns to obtain a homogenized lysate. The quality of the RNA samples 
was confirmed using an Agilent 2100 Bioanalyzer with an RNA 6000 NanoKit for analysis. 
The RIN values were 10 for all samples (Table 5.4). cDNA was synthesized from 1 µg of 
DNA-free total RNA in a 20 µL reaction volume using a Maxima First Strand cDNA 
Synthesis Kit for RT-qPCR. The obtained cDNA samples were diluted 20-fold for RT-PCR 
reactions. Transcription levels for each specific gene were determined in a 20 µL reaction 
volume using Maxima SYBR Green/ROX qPCR Master Mix on a CFX96 real-time PCR 
machine (CFX Manager Version: 3.1.1517.0823, Bio-Rad). Gene expression was 
analyzed using the relative quantification method. The relative quantification method 
estimates the level of gene expression against the control. The control samples were 
W12E cells treated with 0.1% DMSO, used as a vehicle for polyamides. Real-time PCR 
reactions of four cDNA samples (control, samples treated with NV1078, NV1042, and 
NV1011) using the same primer sets, seven DDR target (Table 5.5) and five control genes 
(Table 5.6) were analyzed together in the same 96-well plate in order to use the same 
threshold setting for determination of the quantification cycle values (Cq). 
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Data analysis: Post PCR quality control. Gene expression had been analyzed 
using the relative quantification method (RQ) named also comparative Cq method which 
estimates the level of gene expression against the calibrator. In this case, the calibrator 
sample is W12E cells treated just with 0.1% DMSO vehicle. Five reference genes were 
used as a loading control to show that the efficiencies of the target DDR genes and control 
amplification are approximately equal. 
The typical use of a single gene for normalization leads to errors. Instead, the 
geometric mean of multiple housekeeping genes (optimal number varies from one to more 
than ten (146)) was validated as an accurate normalization factor. The expression of 
reference genes used should not change in the cells under examination or in response to 
experimental treatment.  
 In this work, the Vandesompele (147) normalization strategy was used, which 
employs the calculation of a normalization factor based on three to five reference genes. 
The expression stability for a particular gene is reflected by the M value calculated by the 
Bio-Rad CFX Manager 3.1 software  and represents  the mean standard deviation of the 
log-transformed expression ratios across samples for the particular gene relative to other 
reference genes in the gene panel (146). 
The most stable reference genes are those with the lowest CV and M value. The 
recommended stability values for samples are:  
(1) Mean CV value ≤ 0.25 and Mean M value ≤ 0.5 for homogeneous sample, and  
(2) Mean CV value < 0.5 and Mean M value < 1 are considered acceptable for 
heterogeneous samples. 
The plots of fluorescence vs. cycle number are presented in the supplementary 
information at the end of the chapter. The raw quantification cycle values for the biological 
replicates are presented in Tables 5.7, 5.9, 5.11, 5.13, and 5.15. 
Tables 5.7, 5.9, 5.11, 5.13, and 5.15 present the quantification cycle (Cq) number, 
previously known as the threshold cycle (Ct). The first seven columns show the values 
associated with the DDR genes mentioned in the raw above the table. The last five 
columns display the Cq values related to the reference genes. The reference genes have 
a high expression level compared with the DDR genes. 
  Figures 5.5 – 5.9, display the effects of the three different polyamides for the 
biological replicates according to the normalized relative expression (RQ=2ΔΔCq) values of 
the seven DDR genes to four reference genes. Although the study employed five 
reference genes, just four were used in the normalization process. ATCB was not found 
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to be stably expressed and was eliminated from calculations. Expression stability for a 
particular gene was assessed based on the M value. The normalization aim was to use 
reference genes that give a mean CV value ≤ 0.25 and a mean M value ≤ 0.5 (see Data 
































Table 5.7.  Cq values of qPCR experiments of C-1 Series, 1th biological replicate. C-1: 
control 0.1% DMSO-1, 78-1: NV1078-1, 42-1: NV1042-1, 011-1: NV1011-1.  ECF4165, 
4/11/16  
 




Figure 5.5. Downregulation of DDR genes in cells treated with polyamides. C-1 Series, 
1th biological replicate Relative normalized expression (RQ) associated with Table 7 
Table 5.8. Reference genes stability values associated with qPCR experiments of C-1 
Series 
C-1 Reference gene Coeficient variance M value 
1 PGK1 0.1675 0.3140 
2 GAPD 0.0441 0.2375 
3 PPIA 0.0758 0.2345 
4 RPL13A 0.2152 0.4699 
 Mean value 0.13 0.31 
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample C-1 C-1 C-1 C-1 C-1 C-1 C-1 C-1 C-1 C-1 C-1 C-1
Cq 23.61 21.82 21.67 23.38 20.20 22.88 20.98 16.83 18.98 15.13 15.32 17.49
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample 78-1 78-1 78-1 78-1 78-1 78-1 78-1 78-1 78-1 78-1 78-1 78-1
Cq 23.34 21.42 21.40 23.20 19.87 22.39 20.73 15.43 18.59 14.55 14.77 16.10
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample 42-1 42-1 42-1 42-1 42-1 42-1 42-1 42-1 42-1 42-1 42-1 42-1
Cq 24.01 21.82 21.72 23.41 20.48 22.92 20.83 15.91 19.06 14.78 15.05 16.45
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample 011-1 011-1 011-1 011-1 011-1 011-1 011-1 011-1 011-1 011-1 011-1 011-1







Table 5.9. Cq values of qPCR experiments of C-2 Series, 2th biological replicate. C-2: 
control 0.1 % DMSO-2, 78-2: NV1078-2, 42-2: NV1042-2, 011-2: NV1011-2.  ECF4157, 
4/4/16 





Figure 5.6. Downregulation of DDR genes in cells treated with polyamides. C-2 Series, 
2th biological replicate. Relative normalized expression (RQ) associated with Table 9. 
Table 5.10. Reference genes stability values associated with qPCR experiments of C-2 
Series 
C-2 Reference gene Coeficient variance M value 
1 PGK1 0.1775 0.3973 
2 GAPD 0.1367 0.3430 
3 PPIA 0.3088 0.5395 
4 RPL13A 0.0350 0.3046 
 Mean value 0.1645 0.3046 
 
Content Unk n Unk n Unkn Unkn Unkn Unkn Unkn Unkn Unk n Unk n Unkn Unkn
Sample C-2 C-2 C-2 C-2 C-2 C-2 C-2 C-2 C-2 C-2 C-2 C-2
Cq 23.56 21.91 22.51 24.16 20.87 23.16 21.08 17.86 21.29 16.96 15.98 18.69
Content Unk n Unk n Unkn Unkn Unkn Unkn Unkn Unkn Unk n Unk n Unkn Unkn
Sample 78-2 78-2 78-2 78-2 78-2 78-2 78-2 78-2 78-2 78-2 78-2 78-2
Cq 23.18 21.29 21.48 23.36 19.77 22.78 20.26 16.44 19.17 15.26 15.32 17.19
Content Unk n Unk n Unkn Unkn Unkn Unkn Unkn Unkn Unk n Unk n Unkn Unkn
Sample 42-2 42-2 42-2 42-2 42-2 42-2 42-2 42-2 42-2 42-2 42-2 42-2
Cq 22.53 21.08 21.39 23.16 20.14 22.46 20.40 16.77 19.05 15.07 14.95 17.01
Content Unk n Unk n Unkn Unkn Unkn Unkn Unkn Unkn Unk n Unk n Unkn Unkn
Sample 011-2 011-2 011-2 011-2 011-2 011-2 011-2 011-2 011-2 011-2 011-2 011-2







Table 5.11. Cq values of qPCR experiments of C-3 Series, 3th biological replicate. C-3: 
control 0.1 % DMSO-3, 78-3: NV1078-3, 42-3: NV1042-3, 011-3: NV1011-3.  ECF4148, 
3/31/16 
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Figure 5.7. Bar chart showing downregulation of DDR genes in cells treated with 
polyamides. C-3 Series, 3th biological replicate. Relative normalized expression (RQ) 
associated with Table 11. 
 
Table 5.12. Reference genes stability values associated with qPCR experiments of C-3 
Series 
C-3 Reference gene Coeficient variance M value 
1 PGK1 0.2379 0.5294 
2 GAPD 0.1598 0.4743 
3 PPIA 0.3525 0.6079 
4 RPL13A 0.1648 0.4384 
 Mean value 0.2288 0.5217 
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample C-3 C-3 C-3 C-3 C-3 C-3 C-3 C-3 C-3 C-3 C-3 C-3
Cq 21.55 20.20 20.20 22.18 18.59 21.22 19.14 17.58 20.38 14.63 14.54 18.28
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample 78-3 78-3 78-3 78-3 78-3 78-3 78-3 78-3 78-3 78-3 78-3 78-3
Cq 21.90 19.45 19.93 21.19 18.53 20.55 18.60 13.82 17.59 13.21 13.60 15.78
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample 42-3 42-3 42-3 42-3 42-3 42-3 42-3 42-3 42-3 42-3 42-3 42-3
Cq 21.77 19.79 20.30 21.66 18.73 21.17 18.83 14.14 18.05 13.38 13.50 16.30
Content Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn Unkn
Sample 011-3 011-3 011-3 011-3 011-3 011-3 011-3 011-3 011-3 011-3 011-3 011-3







Table 5.13. Cq values of qPCR experiments of C-4 Series, 4th biological replicate. C-4: 
control 0.1 % DMSO-4, 78-4: NV1078-4, 42-4: NV1042-4.  ECF4177, 5/26/16 
 






Figure 5.8. Bar chart showing downregulation of DDR genes in cells treated with 
polyamides. C-3 Series, 3th biological replicate. Relative normalized expression (RQ) 
associated with Table 13 
 
 
Table 5.14. Reference genes stability values associated with qPCR experiments of C-4 
Series 
 
C-4 Reference gene Coeficient variance M value 
1 PGK1 0.2317 0.5139 
2 GAPD 0.2390 0.5364 
3 PPIA 0.1609 0.4096 
4 RPL13A 0.0326 0.3243 
 Mean value 0.1660 0.4460 
  
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample C-4 C-4 C-4 C-4 C-4 C-4 C-4 C-4 C-4 C-4 C-4 C-4
Cq 23.51 22.12 22.33 24.71 23.10 23.86 21.22 14.91 21.55 16.32 16.25 18.74
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample 78-4 78-4 78-4 78-4 78-4 78-4 78-4 78-4 78-4 78-4 78-4 78-4
Cq 24.17 22.23 22.74 25.19 23.34 23.75 21.66 13.44 21.00 16.29 16.66 18.77
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample 42-4 42-4 42-4 42-4 42-4 42-4 42-4 42-4 42-4 42-4 42-4 42-4






Table 5.15.  Cq values of qPCR experiments of C-5 Series, 5th biological replicate. C-5: 
control 0.1 % DMSO-5, 78-5: NV1078-5, 42-5: NV1042-5, 011-5: NV1011-5.  ECF4170, 
4/22/16 





Figure 5.9. Bar-chart showing downregulation of DDR genes in cells treated with 
polyamides. C-5 Series, 5th biological replicate. Relative normalized expression (RQ) 
associated with Table 15 
Table 5.16. Reference genes stability values associated with qPCR experiments 
of C-5 Series 
 Reference gene Coeficient variance M value 
1 ACTB 0.0259 0.1165 
2 PGK1 0.0573 0.1377 
3 GAPD 0.0904 0.1911 
4 RPL13A 0.0866 0.1817 
 Mean value 0.0650 0.1567 
 
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample C-5 C-5 C-5 C-5 C-5 C-5 C-5 C-5 C-5 C-5 C-5 C-5
Cq 23.92 22.12 22.20 24.42 22.49 23.12 21.08 14.56 19.08 15.45 15.76 17.54
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample 78-5 78-5 78-5 78-5 78-5 78-5 78-5 78-5 78-5 78-5 78-5 78-5
Cq 23.95 22.09 22.06 24.65 22.82 23.37 21.39 14.72 19.27 15.58 15.89 17.37
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample 42-5 42-5 42-5 42-5 42-5 42-5 42-5 42-5 42-5 42-5 42-5 42-5
Cq 24.02 22.41 22.39 24.91 23.00 23.42 21.73 14.81 19.25 15.94 14.48 17.65
Content Unkn Unkn Unkn Unkn Unk n Unkn Unkn Unkn Unkn Unk n Unk n Unkn
Sample 011-5 011-5 011-5 011-5 011-5 011-5 011-5 011-5 011-5 011-5 011-5 011-5







The selected genes’ expression was altered in all five biological replicates. Series 
1, 2, and 3 presented the same trend in gene regulation.  All genes were downregulated. 
The similarities between the effects induced by the two active polyamides and the effect 
induced by the NV1011 polyamide were unexpected. It was thought that the small NV1011 
polyamide (Table 2) was inactive, and therefore will not have any effect on the cells. 
All samples have been treated with 0.1 µM polyamide. Table 5.17 illustrates the 
relationship between the IC50 and IC90 values (Chapter 1) and the experimental 
concentration. 
 
Table 5.17. The IC50 and IC90 values and their relationships to 0.1 µM concentration 
Polyamide IC50 (µM) IC90 (µM) 0.1µM/IC50 0.1µM/IC90 
NV1078 0.046 0.307 2.2 0.3 
NV1042 0.036 0.351 2.8 0.3 
 
The polyamide concentration used for the treatment of the cells was 2.8 times higher 
than the IC50 of the NV1042 polyamide, and 2.2 times greater than the IC50 of NV1078, 
determined in the same conditions. Consequently, when interpreting the changes in the 
level of expression for the same gene, this difference has to be taken into consideration.  
ΔΔCq was calculated for each target gene against the average of four control 
genes. For the first three samples, this method produced 9 pair-wise comparisons for each 
gene (3 DMSO treated ΔCq values x 3 PA treated ΔCq values) (6). The genes are 
considered affected by polyamide treatment if at least 2 fold (|ΔΔCq| ≥ 1) or more change 
was registered in their expression compared with the same gene expression in samples 
treated with 0.1% DMSO (control) (6). The value ΔΔCq = 1, accounts for RQ = 2 ΔΔCq = 2, 









Figure 5.10 Gene expression downregulation induced by NV1078, NV1042 and 
NV1011. All 9 ΔΔCq values are shown as well as the median line and the average (x) 




Taking into consideration that the ATM pathway activated by double-stranded 
breaks and the ATR pathway activated by single-stranded breaks are linked to each other 
as demonstrated by recent studies reviewed by Hong and Laimins (15) it makes sense to 
have the same trend for ATM/CHEK2 and ATR/CHEK1 pairs. ATR seems to be 
subordinated to elements of ATM. The ATR–CHK1 pathway requires activation by ATM. 
(15).  
In our case, the regulation of ATM was also correlated with the regulation of 
downstream element P53. In the same way, the regulation of ATR was associated with 
the expression levels of Rad9, Rad1, and P53. Their expression was also downregulated. 
We already know that the large polyamide NV1042 induces a DDR response in 
the cells infected with the HPV16 virus (5, 6, 117).  We also know from the same study 
that ATM is important for episome maintenance (6) because the siRNA-mediated 
knockdown of the gene drastically decreased the episome numbers in W12E cells.  
It was also demonstrated that the significant viral loss registered when infected 
cells were treated with the same NV1042 active polyamide is a consequence of the 
degradation of the viral episome, not just the inhibition of viral DNA replication (117). 
Therefore, it may be postulated that the downregulation of the DDR elements registered 
in samples treated with NV1042 and NV1078 polyamides is a direct consequence of the 
episome degradation. The present results reinforce the principle that the episome 


















Table 5.18. Comparison of gene expression altered by NV1042 (PA25) in W12E cells, 
induced in two different conditions. W12E cells were incubated with 10µM NV1042 for 48 
hours (6), and this work, W12E cells were incubated with 0.1µM NV1042 for 24 hours 
(biological replicate  #3), Fold Δ: 2 ΔΔCq  
 
 
Human Gene mRNA (Fold 
Δ)(6) 
 mRNA (Fold Δ) Function/Pathway 
Ataxia Telangiectasia 
Mutated, ATM 
-3.68  -3.5 (2 1.8 ) HR, DSB Repair,  
PI-3 kinase 
Ataxia Telangiectasia 
and Rad3 Related, ATR 
…  -2.3 (2 1.2 ) HR, SSB Repair 
Rad1 Homolog, RAD1 
 
-67.65  -3.3 (2 1.7 ) 9-1-1 member, 
exonuclease 
Rad9 Homolog, RAD9A 
 











-2.62  -3.0 (2 1.6 ) DDR ATM 
checkpoint 
effector 
Tumor Protein P53, 
TP53 












downregulated 7/9 5 7/9 5 7/9 6
upregulated 2/9 0 2/9 0 2/9 0
downregulated 7/9 6 7/9 5 7/9 5
upregulated 2/9 0 2/9 0 2/9 0
downregulated 7/9 4 8/9 4 7/9 4
upregulated 2/9 0 1/9 0 2/9 0
downregulated 7/9 4 7/9 4 7/9 4
upregulated 2/9 0 1/9 0 1/9 0
downregulated 8/9 5 7/9 5 8/9 4
upregulated 1/9 0 1/9 0 1/9 0
downregulated 7/9 5 7/9 6 7/9 5
upregulated 2/9 0 2/9 0 2/9 0
downregulated 7/9 5 7/9 5 7/9 4














HR: Homologous recombination, exchange of base-paired partners between two 
homologous DNA molecules (113) 
CHEK1,2: checkpoints, places in the cell cycle where DNA sequence and structure 
fidelity are ascertained before progression to the subsequent phase of the cell 
cycle (113) 
STAT5: Signal transducer and activator of transcription  
qPCR:  quantitative real-time PCR (145) 
RT-qPCR: reverse transcription quantitative real-time PCR (145) 
Reference genes: previously known as housekeeping or control genes (145) 
Quantification cycle Cq: previously known as the threshold cycle (Ct), the cycle 





















5.6 Supplementary Information 
 
 
Figure S1. Electropherograms of extracted RNA; quality and integrity of the RNA were 




The Analysis of Viral and Human Transcriptomes After Treatment of W12E Cells 
with Polyamides 
6.1 Introduction 
Based on the knowledge gathered from the results of the binding studies in 
Chapters 3 and 4 and those reported recently (11, 105), coupled with the first gene 
expression array work on a limited but important set of mRNA levels (6), a complex study 
concerned with genome-wide expression was designed. With the help of high-throughput 
sequencing (HiSeq techniques) host and viral mRNA expression will reveal any genes 
regulated by the polyamides. Thus, the aim of this gene expression project is to find the 
similarities and differences in different polyamides’ mechanism of action related to gene 
expression by quantifying messenger RNA (mRNA) after treatment of HPV-infected 
keratinocyte (W12E) cells separately with eight polyamides (Table 6.1). The viral 
transcriptome data obtained after the treatment of cells with polyamides will be compared 
with the known viral transcriptomes (148, 149) and to each other. By comparing samples 
treated with different polyamides, different expression levels and different splicing sites 
may be revealed (150). 
The HPV mRNA is polycistonic in both the episomal form and when integrated into 
human chromosomes (21, 148-150). In undifferentiated cells, the transcription is initiated 
by the early promoter (p97) and is terminated at the early poly(A) signal, AE, while the 
mRNA encoding the viral early genes is produced. In differentiated cells, the transcripts 
are expressed by the late promoter (p670) and utilize a late poly(A) signal, AL, while they 
produce mRNA for the late genes (45).  The transcripts in this situation are terminated at 
the late poly(A) signal (Figure 6.1) (46). By checking the level of E6 and the late L1 and 
L2 genes, it is possible to assess the replication phase of the virus.  
The human transcriptome data obtained after sequencing results are fully-
processed will aid in understanding how polyamides help infected cells eliminate the 





Figure 6.1. The HPV genome circular dsDNA structure (46) 
 
6.2 Materials and Methods  
A detailed description of the cell culture (5.3.1), polyamide treatment (5.3.2), and 
RNA extraction (5.3.3) methods is provided in Chapter 5. 
For the RNASeq experiment, an inactive polyamide (NV1011) and 7 active 
polyamides were used. Among the active polyamides are the two, PA1 and PA42, leading 
compounds of the HPV viral research. Three TMG compounds NV1078, NV1087 and 
NV1113, and two guan compounds NV1111 and NV1115 (Chapter 1, Table 1.2) were 
chosen because of their excellent potency in cell cultures harboring HPV 16 or HPV 18.  
 
Table 6.1. Polyamides used for RNASeq studies. The IC50 and IC90 values 
measured in W12E cells were determined by T. G. Edwards in the Fisher lab (unpublished 
data). 
PA HPV16 IC50 [µM] HPV16 IC90 [µM] HPV18 IC50 [µM] HPV18 IC90 [µM] 
NV1011 (PA11) NOT ACTIVE NOT ACTIVE NOT ACTIVE NOT ACTIVE 
NV1028 (PA1) 0.100 1.113 0.717 >10 
NV1042 (PA25) 0.036 0.351 0.056 1.462 
NV1078 0.046 0.307 0.030 0.091 
NV1087 0.031 0.200 0.024 0.297 
NV1111 0.017 0.121 0.018 0.136 
NV1113 0.304 >10 0.228 >10 
NV1115 0.103 0.378 0.167 0.937 
 
6.2.1 TruSeq Stranded mRNA Library Preparation 
All total RNA samples used for library preparation were of excellent quality 
(RIN=10, see Chapter 5) and high concentration (Table 5.4 and Figure S1 in Chapter 
100 
 
5), and had fallen into the range recommended by ILLUMINA for sequencing is (0.1 - 4) 
µg/mL. 
The total RNA (tRNA, not meaning transfer RNA in this context) samples stored at 
-800C were used for preparing the NextGen sequencing libraries according to TruSeq 
Stranded mRNA Library LS Prep protocol for 45 samples using 9 adapters (Illumina, 
RS122-2102 set B Kit). The adapter includes the index, a unique sequence of 6 
nucleotides. The index is used to identify the sample. Different input quantities, ranging 
from 500 to 1000 ng of total RNA, were used to allow the determination of the ideal amount 
for preparing a complementary ds DNA library with the selected method. The best library 
quality was obtained using lower tRNA quantities (Table 6.3). Therefore, the majority of 
libraries were prepared from 500 ng total RNA as starting material.  
The tRNA samples were subjected to a series of steps to obtain ds cDNA ready 
for sequencing. The first step was the purification of messenger RNA (mRNA) from total 
RNA and its subsequent fragmentation. In this way, non-polyA RNA, or ribosomal RNA, 
was separated from the pool of interest. PolyA mRNA was purified using polyT-oligo-
attached magnetic beads provided with the Illumina kit. Two rounds of elution were 
performed. During the first round of purification, the mRNA was denatured and bonded to 
the PolyT sequences attached to the beads. During the second purification, mRNA was 
fragmented into small pieces with a median size of 150 bp, using divalent cations under 
elevated temperature. The purified and fragmented mRNA was primed with random 
primers for cDNA synthesis. 
The purified and fragmented mRNA was primed with random primers for cDNA 
synthesis in the presence of reverse transcriptase SuperScript II. This process reverse 
transcribed the cleaved RNA fragments primed with random hexamers into first strand of 
cDNA. Actinomycin improved the specificity of the process, allowing RNA-dependent 
synthesis. For the interpretation of the RNA-seq results only the first cDNA strand, which 
is the anti-sense strand, is sequenced. During the process of the second strand cDNA 
synthesis, the template mRNA was removed, and the complementary strand generated 
the final ds cDNA.  
Agencourt PAMPure XP beads, which selectively bind DNA sequences longer than 
100 bp, were used to capture the ds cDNA from the second strand reaction mix. To the 
generated, blunt-ended, ds cDNA, a single “A” was added to the 3’ ends to which a 
corresponding single “T” at 3’ end of the adapter makes available a complementary 
overhang for ligating the adapter to the fragment. 
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Different y-shaped indexing adapters were ligated to the ends of different ds cDNA 
samples (Table 6.2) with the use of T4 DNA ligase. The adapters contain the (1) 
sequencing primers, (2) the index sequence and (3) oligonucleotides complementary to 
the sequencing machine’s flowcell DNA sequences. Thus, the adapters hybridize with the 
flowcell oligos.  
Table 6.2. Adapters associated with different samples 
Sample (1-9) Adapter Index Sequence 
NV1078 AR001 ATCACG(A) 
NV1087 AR003 TTAGGC(A) 
NV1042 AR008 ACTTGA(A) 
NV1028 AR009 GATCAG(A) 
NV1111 AR010 TAGCTT(A) 
Control 0.1% DMSO AR011 GGCTAC(A) 
NV1011 AR020 GTGGCC(T) 
NV1113 AR022 CGTACG(T) 
NV1115 AR025 ACTGAT(A) 
 
To increase the amount of ds cDNA, enrichment with PCR was performed with a 
Primer Cocktail that anneals just to the ends of the adapters. In this way, just ds DNAs 
that have adapters ligated to the both ends will be amplified. After a new purification with 
AMPure XP beads the quantity and the quality of libraries were evaluated.   
6.2.2 NextGen Library Quality Control. Validation and Quantification of 
TruSeq library  
The size distribution after fragmentation of ds cDNA and adapter ligation was 
assessed on a BioAnalyzer Agilent 2100 instrument according to the Agilent DNA 1000 
Kit (5067-1504) protocol. The results are presented in Table 6.2. In addition, a Qubit 2.0 
Fluorometer was employed to determine the concentration of the TruSeq library with the 
help of Qubit dsDNA BR Assay Kit, catalog no. Q32850. The molar concentration of the 
samples was estimated by averaging the concentrations of both Qubit and BioAnalyzer 
measurements. The molar concentration was double-checked with a Qubit 3.0 
Fluorometer at DNA Core Facility, University of Missouri, Colombia. 10 nM stock libraries 
were used to prepare DNA templates for cluster generation.  
6.2.3 Sequencing and Alignment 
The subsequent work, pooling of the libraries and sequencing on HiSeq 2500 
Illumina instrument, was performed by Nathan Bivens and his colleagues at the DNA Core 
Facility, University of Missouri, Colombia. The sequencing results’ interpretation is being 
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performed at Informatics Research Core Facility (IRCF) by Christopher Bottoms under the 
supervision of Dr. Scott Givan 
The latent Illumina adapter sequences were identified and removed from the RNA-
Seq data using bcl2fastq version 2.17.1.14 (run with command-line parameters "--
minimum-trimmed-read-length=10 --mask-short-adapter-reads=9").  Subsequently, input 
RNA-Seq data was trimmed and filtered to remove low quality nucleotide calls and whole 
reads, respectively, using the Fastx-Toolkit, version 0.0.13.  From the remaining RNA-Seq 
data, foreign or undesirable reads were removed by sequence matching to filter 
sequences, using Bowtie, version 0.12.9. Filter sequences included the following (National 
Center for Biotechnology Informatics accessions in parentheses): Phi-X genome 
sequence (NC_001422.1), the pUC19 vector (M77789.2), human ribosomal RNA 
sequences, the human mitochondrial genome (from Genomic Reference Consortium 
assembly h38), an additional human mitochondrial sequence (NCBI accession S64650.1), 
and Human genomic repeat elements in RepBase, version 20.02. The remaining RNA-
Seq data was subjected to genome alignment, transcript assembly and expression 
quantification using TopHat, version 2.1.0, via the RNA-Seq-Toolkit 
(https://github.com/sgivan/RNA-Seq-Toolkit, (151) The differential expression analysis 
was done using Cufflinks and Cuffdiff, version 2.2.1.  Computational hardware used 
included the BioCluster of the Informatics Research Core Facility (University of Missouri) 
and the Lewis Cluster of Research Computing Support Services (University of Missouri). 
Just unique reads-anti-sense expression of the transcripts is being used since the 
library was prepared using a strand specific preparation kit that only sequenced the 
first cDNA strand.  
Analysis of the summary file will lead to the discovery of transcripts that are 
statistically differentially expressed in these data. 
6.3 Partial Results  
The size distribution of the TruSeq stranded mRNA libraries after adapter ligation 
shows ideal distribution, 260 bp, as can be seen in the profiles generated by Agilent 2100 
Bioanalyzer (Supplementary Figures). The molar concentration of the 45 libraries is 








Table 6.3. TruSeq Stranded mRNA Libraries characteristics. The table includes the amount of total 
RNA used for library preparation, and the average size and the concentration of ds DNA, 
determined with BioAnalyzer Agilent 2100. The molar concentration was calculated with 













 Size (bp) 
NV1078-1 628 18.75 88.35 327 
NV1028-3 500 24.83 125 306 
0.1%DMSO-1 1000 20.27 98.2 317 
NV1087-1 500 11.67 57.63 312 
NV1042-1 500 20.92 105.69 305 
NV1028-1 500 13.46 69.6 298 
NV1111-1 500 22.79 118.23 297 
NV1042-2 500 14.64 78.33 288 
NV1078-2 738 20.27 104.11 300 
NV1087-2 690 18.6 97.48 294 
NV1028-2 944 24.06 127.4 291 
NV1111-2 670 28.23 152 286 
0.1%DMSO-2 542 15.41 81.32 292 
NV1078-3 500 22.37 115.67 298 
NV1087-3 500 18.86 97.85 297 
NV1111-3 500 24.62 127.73 297 
0.1%DMSO-3 500 17.48 94.84 284 
NV1042-3 500 17.67 92.29 295 
NV1011-1 500 14.25 73.68 298 
NV1113-1 500 15.04 74.76 310 
NV1115-1 500 7.04 38.6 281 
NV1011-2 500 15.14 75.99 307 
NV1113-2 500 15.16 76.09 307 
NV1115-2 500 13.52 71.73 284 
NV1011-3 500 19.74 108.24 281 
NV1113-3 500 20.67 103.74 307 
NV1115-3 500 43.68 213.66 315 
NV1078-4 500 22.47 116.57 297 
NV1087-4 500 23.93 119.33 309 
NV1042-4 500 17.16 86.41 306 
NV1028-4 500 17.71 91.88 297 
NV1111-4 500 29.77 150.89 304 
0.1%DMSO-4 500 24.59 127.14 298 
NV1011-4 500 19.55 99.42 303 
NV1113-4 500 23.3 116.19 309 














 Size (bp) 
NV1078-5 500 19.89 102.16 302 
NV1087-5 500 22.09 113.46 301 
NV1042-5 500 18.51 97 294 
NV1028-5 500 35.52 186.8 293 
NV1111-5 500 31.02 159.32 300 
0.1%DMSO-5 500 35.9 180.18 307 
NV1011-5 500 17.27 85.29 312 
NV1113-5 500 20.67 108.7 293 
NV1115-5 500 22.88 111.92 315 
 
The nine samples (a biological replicate series) were multiplexed per lane, and 
every set of sample was run in three lanes to obtain a statistically relevant amount of reads 
(50M). The possibility of pooling the maximum of 9 samples together in one lane was 
verified prior to library preparation with Illumina Experiment Manager (IEM) software. 
The sequencing runs were of high quality Q30 score was over 90%, % PF clusters 
over 90, and the perfect barcode over 99% for every sample (Flowcell Summary and Lane 
Summary ECF4172-4175). 
 
6.4 Overall conclusions 
To treat current or future HPV infections, drugs that selectively block virus-specific 
processes, but do not damage the host cells, are needed. The compounds developed in 
Dr. Bashkin’s lab are unique imidazole-pyrrole polyamides which have anti-HPV activity. 
Biophysical studies of two TMG asymmetric hairpin polyamides (NV1078 and 
NV1087) on HPV LCR segment revealed that although the polyamides bind in many 
different sites, they have a noticeable preference for the region adjacent and overlapping 
with the E1, E2 binding sites (Figure 4.11). The intensive binding in the minor groove of 
dsDNA (sequence 7880-30 of HPV16 and sequence 7841-43 of HPV18) of TMG-AHPs 
structurally alter the dsDNA. The required adjustments of the DNA to allow binding may 
cause the inability of E1/E2 to assemble, as a replication competent double-hexamer at 
the ORI, obstructing the replication process at the start. The intensive binding in the region 
mentioned above may also cause ssDNA exposure or double strand breaks within HPV 
DNA and the activation of DNA damage response pathways (6). Multiple binding sites 
induce DNA nicks which activates ATR and ATM.  
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The partial results of gene expression analysis exposed genes that are relevant to 
the polyamide mechanism of action. After treatment of W12E cells with active polyamides 
a downregulation of ss and ds signal transducers ATM and ATR was registered. The 
regulation of ATM was also correlated with the regulation of downstream element TP53. 
In the same way, the regulation of ATR was associated with the expression levels of Rad9, 
Rad1, and P53. Their expression was also downregulated. The downregulation of the 
DDR elements registered in samples treated with NV1042 and NV1078 polyamides is a 
direct consequence of the episome degradation. The present results reinforce the principle 
that the episome degradation was accomplished by the polyamide treatment. 
Our findings complement the notion that the PA binding to negatively supercoiled 
HPV episomes activate the DNA damage response (DDR) pathways (6). Activation of 
DDR genes eliminates the viral episomes without having substantial effects on cell growth 
or apoptosis (6).  
The elimination of viral DNA during the maintenance stage it is an effective strategy 
for the development of antiviral compounds. The large Im-Py polyamides synthetized in 
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